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Abstract
The study of antigen-specific intrathecal oligoclonal bands is well established and a 
number of methods have been used to demonstrate that the relative affinity of the 
antibody produced in multiple sclerosis is low, and in encephalitis, high. A method 
colloquially known as Eastern blotting was developed whereby relative affinity of 
individual clones, rather than total antibody, could be studied and quantified by antigen 
immunoblotting and investigation of a digitised blot using image-manipulating 
software. This method was used to show that the pixel density of a band in CSF was 
significantly greater than the same band in serum in a patient with SSPE, and was thus 
of intrathecal origin. Eastern blotting was then used on a series of samples from a 
patient with herpes encephalitis to demonstrate that affinity maturation of the immune 
response had occurred intrathecally. The method was used qualitatively to investigate a 
proposal that Acinetobacter sp. infection could be the primary cause of multiple 
sclerosis: no evidence could be found to support the hypothesis. Another suggested 
cause of multiple sclerosis, Chlamydophila pneumoniae, was studied using a variety of 
methods including Western blotting. Again, there was no evidence to support the 
hypothesis. During the project, an unexpected effect of high-strength thiocyanate was 
revealed, and limited study of this suggested that thiocyanate had an effect on IgG, 
possibly related to the age of the sample.
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1.0 Introduction
1.1 B Cell Ontogeny
1.1.1 Introduction to B cell Ontogeny
The immune system is a combination of specialised cells and molecules that mediates 
two different types of response to antigenic stimulus. The innate, or natural, response is 
always the same regardless of how many times a particular stimulus is met but the 
acquired, or adaptive, response improves on repeated exposures.
Phagocytes, natural killer cells, inflammatory mediators, acute phase proteins, some 
cytokines and complement mainly mediate the innate response. The acquired response 
is mediated by B and T lymphocytes and immunoglobulins secreted by the B cells. The 
immune response to any given stimulus is usually a combination of both.
Both B cells and T cells derive from a common lymphoid progenitor (CLP), itself 
derived from a pluripotent haemopoietic stem cell, B cells accounting for 5 to 15% of 
the circulating lymphoid cell population.
In the chicken, primary B cell development occurs in the bursa of Fabricius, hence the 
title B or bursal lymphocytes. In mammals, it begins in the foetal liver at approximately 
eight to nine weeks’ gestation after which the bone marrow assumes B cell production, 
where it remains for life.
In brief, the stem cell first becomes a pre-pro-B cell, at which point it is committed to 
becoming a B cell. It then matures successively into a pro-B, pre-B, immature B, 
transitional B and mature B cell (Figure 1.1). Each stage can be classified according to 
the surface and cytoplasmic markers expressed. Maturation is characterised by the 
rearrangement and expression of immunoglobulin genes.
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Figure 1.1 B lymphocyte differentiation.
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1.1.2 Stem cell to pre-pro-B cell
The pluripotent haemopoietic stem cell (PHSC) is thought to give rise to common 
myeloid- and lymphoid-restricted progenitors (Weissman, 2000), the latter giving rise to 
both B and T lymphocytes. In the bone marrow, the stem cell lies close to the endosteal 
cell layer at the edge of the bone marrow cavity.
There are three known essential transcription factors which initiate B lymphopoiesis 
from the PHSC: E2A and early B cell factor (EBF) (Rolink et al, 2001) do not 
determine B cell commitment unlike Pax5 (Nutt et al, 1999), although it is not known 
whether or not the commitment is reversible.
The pre-pro-B cell can now be distinguished from its CLP precursor by the cell surface 
markers, cluster of differentiation (CD) 43 and CD45R.
1.1.3 The pro-B cell to mature B cell
Once the stem cell has matured into the pro-B cell it expresses the CD 10 surface 
antigen, the common acute lymphoblastic leukaemia antigen (CALLA), which is 
specific for pre-B cells. The pro-B cell also differs from its precursors because 
immunoglobulin gene recombination begins and they express a forerunner of the B cell 
receptor (BCR).
The immunoglobulin molecule consists of two heavy chains joined by a disulphide 
bridge, and two light chains, each attached to one of the heavy chains through a 
disulphide bridge. Where the light and heavy chains run parallel they form two antigen- 
binding sites with their variable domains (Edelman, 1973). Each chain has a constant 
(C) region, which determines the chain type or class. In order to produce antibodies 
with different antigen specificities an individual must therefore have the genetic 
“ability” to produce a large number of variable (V) domain sequences. Dreyer and
16
Bennett (1965) proposed that separate “genes”, which underwent rearrangement, coded 
for V and C regions. It has been estimated that about 1015 variable regions can be 
produced from fewer than 400 genes (Tonegawa, 1983).
The use of recombinant deoxyribonucleic acid (DNA) technology and restriction 
enzymes showed that genes for immunoglobulins, unlike most genes, were not intact 
and functional but were broken up along the chromosome into gene segments (Hozumi 
and Tonegawa, 1976).
The genetic components for immunoglobulins are found on three chromosomes; 
chromosome 14 for the immunoglobulin heavy chain (IGH) cluster, chromosome 2 for 
the immunoglobulin kappa (IGK) (k  or kappa light chain) cluster and chromosome 22 
for the immunoglobulin lambda (IGL) (k or lambda light chain) cluster. Each cluster 
contains gene segments coding for V, joining (J) and C segments. The IGH cluster also 
contains D gene segments coding for diversity (D), (Delves and Roitt, 2000).
The first event in gene rearrangement is the recombination of a D and J segment from 
the IGH cluster on both copies of chromosome 14 followed by the recombination of one 
of these DJ segments with a V segment. If this VDJ recombination is non-productive 
then a VDJ recombination occurs on the other DJ segment. Once a productive VDJ 
recombination has been generated then it is joined to a C segment. There are five of 
these corresponding to the five classes of antibody, G, A, M, D and E. The light chains 
are similarly coded, though without the D segment, and have only one C exon in a 
cluster, hence the production of either X or k  light chains. Thus, VDJC (for heavy 
chain) and VJC (for light chain) recombination form a linear coding unit for that 
particular chain. Immunoglobulins G and A and X light chains all have subclasses. 
Inaccuracies in the splicing of the VDJ junctions can lead to slight variations in the 
nucleotide sequence and terminal deoxynucleotidyl transferase (Tdt) may also insert
17
additional nucleotides thus further increasing diversity (Schatz et al, 1992) and leading 
to a possibly unique immunoglobulin molecule (Figure 1.2).
The pre-B cell can now synthesise M heavy chains that are linked to a “pseudo light 
chain” and presented as a cell surface surrogate “immunoglobulin M (IgM)” receptor. 
This is essential for further differentiation as the receptor is signalled to suppress heavy 
chain gene rearrangement on the sister chromatid: a process called allelic exclusion. 
Gene rearrangements now occur in the /r light chain loci until a productive 
rearrangement is found. The cell can now synthesise conventional surface IgM which 
effects allelic exclusion on the light chain genes thus ensuring the progeny of the cell 
will continue to make the same immunoglobulin chains, the phenomenon called clonal 
restriction.
The cell is now expressing surface IgM, possibly along with immunoglobulin A (IgA), 
immunoglobulin G (IgG) and immunoglobulin D (IgD), which primes the immature B 
cell for antigen response. Tdt and CD 10 have been lost as surface antigens and the cell 
now expresses CDs 19, 20, 21, 23 and 45R alongside Major Histocompatibility 
Complex (MHC) II.
The next stage in the development of the B cell is the first exposure to antigen. To be 
part of the immune response the B cell must express a receptor that will bind the 
antigen, the process of clonal selection. The stronger the binding, the more likely it is 
that the B cell will survive and proliferate.
At this point, it is worth remarking on the two sub-populations of B cells, B1 and B2.
B1 cells develop in the foetus, are located mainly in the peritoneal cavity (Su and 
Tarakhovsky, 2000) and usually express CD5 as a surface marker (Bla), but not always 
(Bib). They produce polyreactive IgM (“natural” antibodies) of low affinity (Hayakawa 
et al, 1999) that are often self-reactive (Hayakawa et al, 1984). B1 cells are positively
18
selected by self-antigens (Hayakawa et al, 1999) and are a self-renewing population that 
may be controlled by secreted IgM (Hayakawa and Hardy, 2000).
The B2 cells that develop later in the bone marrow, few of which express CD5, co­
express IgM and IgD and it is these that proliferate after antigenic stimulus. They do not 
have autoreactivity (Comall et al, 1995).
1.1.4 Affinity Maturation
After antigenic stimulation, B cells mature further into either memory cells or plasma 
cells, in an area within the lymph node called the germinal centre. Once bonding with 
antigen has activated the B cell, it becomes a blast cell, of which a very small number 
form a germinal centre. Surrounded by resting B cells and sustained by follicular 
dendritic cells, B cells proliferate in the dark zone of the germinal centre. Here they 
undergo somatic hypermutation of the variable region genes, which “fine tunes” 
specificity. The proliferating cells migrate to the basal light zone where they stop 
proliferating and begin to upregulate expression of surface immunoglobulin. In here, 
there is extensive positive selection of high-affinity, antigen-specific B cells thought to 
be driven by antigen-antibody complexes deposited on the follicular dendritic cells. 
However, a recent study in transgenic mice unable to secrete IgM showed that the lack 
of immune complexes did not prevent a normal immune response (Hannum et al, 2000). 
The blast cell expresses CD 10 again but only during proliferation. B cells not positively 
selected at this stage apoptose and are subsequently phagocytosed by macrophages, 
becoming “tingible bodies” within the macrophage. B cells that are positively selected 
migrate to the apical light zone where isotype switching occurs. The genetic mechanism 
underlying this is the recombination of the VJ segment with a different C segment.
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Figure 1.2 Generation of antibody diversity.
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Although the antibody specificity remains the same, (as coded for by the V region), the 
different heavy chain isotype can give the immunoglobulin different properties with 
regard to complement binding, receptor interaction and immunoglobulin transfer across 
membranes.
As the antigen concentration decreases only those cells with high affinity receptors will 
be sustained. Those cells now further differentiate into either memory B cells or plasma 
cells under the influence of CD40 or soluble interleukin (IL)-l-a together with CD23, 
respectively. Memory cells enable a faster and better secondary immune response after 
re-encountering the antigen and commonly express IgA or IgG as a surface antigen. 
Plasma cells have no surface immunoglobulin and express different surface markers 
from memory cells. Plasma cells express CD38, which is initially lost during the 
transmission from pre-B cell to immature B cell and plasma cell antigen 1 (PCA-1), a 
unique antigen found only on the plasma cell. Plasma cells mature away from the 
germinal centre and have a well-defined endoplasmic reticulum and Golgi apparatus 
with which they can synthesise and secrete immunoglobulin.
1.2 Antibody Affinity and Avidity
Antibody affinity can be defined as the strength of the binding between an antibody and 
an antigen and is a combination of hydrogen bonds, electrostatic interactions, van der 
Waals forces and hydrophobic bonds. If there is, stoichiometrically, a good fit between 
the binding site of the antibody and the antigenic determinant, or epitope, then many 
attractive forces are created and few repulsive forces so there is antibody-antigen 
binding of high affinity. However, if the fit is poor then repulsive forces dominate so the 
antibody will be of low affinity for that epitope. When the fit is so poor that high 
repulsive forces are generated, there may be no attraction and thus no affinity.
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Affinity relates specifically to a single antigenic determinant binding with a single 
combining site and is not the same as avidity, which is the overall strength of antibody- 
antigen binding, in which either antibody or antigen or both can be multivalent. If all 
binding sites on the antibody can combine with the antigen the avidity will be greater 
than the sum of affinities because all the interactions must be simultaneously 
dissociated.
The ability of an antibody to recognise an antigen lies in the shape of the epitope, a 
combination of stearicity and charge, rather than just its chemical properties. Thus 
antibodies can be very specific and can distinguish subtle differences in epitope 
conformation. However, two or more antigens may share an epitope, in which case 
antibodies raised primarily against one will cross-react with the other. This phenomenon 
is known as molecular mimicry and can lead to autoimmune disease. A classic example 
of a bacterium causing molecular mimicry is Campylobacter jejuni. Following infection 
with Campylobacter, antibodies can be raised against the lipopolysaccharides of the 
organism, which then cross-react with glycolipids in the myelin sheath, leading to 
Guillain-Barre syndrome or Miller Fisher syndrome (Willison and Yuki, 2002).
The affinity and avidity of an antibody are clearly of importance with regards to its 
physiological function. Immune complexes of antigen with high-affinity antibody are 
removed more quickly from the circulation than those involving low-affinity antibodies 
because they are more efficient at activating the complement pathways and stimulating 
neutrophils to release lysosomal enzymes (Marzocchi-Machado et al, 1999).
1.3 Chaotropism
The word ‘chaotrope’ derives from the Greek: Chaos, meaning disorder or confusion, 
and trope, meaning a turning. Thus, a chaotropic molecule acts by disrupting the 
chemical system into which it is introduced.
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The reversible nature of the antibody-antigen bond is the chemical basis on which 
chaotropic molecules, such as sodium thiocyanate (NaSCN), work. In solution, the 
thiocyanate ion, SCN-, is small and highly charged and so can infiltrate the antibody- 
antigen interface. If the antibody-antigen bond is sufficiently “tight”, i.e. the antibody 
has high affinity for the antigen, then a relatively high concentration of the chaotrope 
would be required to exert sufficient “pressure” to disrupt the bond. The less “tight” the 
bond the progressively lower concentration of chaotrope would be needed to disrupt the 
binding and therefore the lower the affinity of the antibody for that antigen.
As all the forces involved in antibody-antigen binding are reversible, then the antibody- 
antigen bond must also be completely reversible and therefore subject to the Law of 
Mass Action which defines the behaviour of a chemical equilibrium of the nature:
A + B <=> C + D 
In terms of antibody-antigen reactions it can be written as
Ab + Ag <=> AbAg
where Ab = antibody, Ag = antigen, AbAg = antibody-antigen complex, <=> = reversible 
reaction.
If the antibody has a high affinity for the antigen the equilibrium will lie over to the 
right. The affinity of the antigen-antibody bond can be defined with the equilibrium 
constant, Ka, of the association reaction:
Ka= [AbAg]/[Ab][Ag] 
where [ ] represents concentration.
The disassociation reaction and its equilibrium constant, Kd, is the inverse
Kd = [Ab][Ag]/[AbAg] 
and its value is the reciprocal of Ka.
The term “affinity” strictly refers to the binding of the antibody to a single antigenic 
determinant whereas in practice antigens are often multivalent and react with polyclonal
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serum derived from either a patient or a commercial source. This interaction, the sum of 
affinities, is called ‘avidity’ or ‘functional affinity’. With a multivalent antigen and a 
polyclonal serum numerous antibodies can simultaneously bind the antigen so that when 
one of the antigen-antibody bonds dissociates the antigen can still be held by the others. 
This means that antigen-antibody binding is greater than the sum of the individual 
affinities, as the Ka values of each bond can be multiplied to obtain the final Kavid, the 
“avidity constant” or “functional affinity constant”.
In practice, the term “affinity” is often used where “avidity” is the correct term, even 
within peer-review journals.
The effects of salts of the thiocyanate ion on antibody-antigen interactions have been 
studied for many years. In 1978, Shimizu et al used potassium thiocyanate to elute anti- 
dinitrophenyl antibodies from an immunoadsorbent. They found that the mean affinity 
of their elutions increased along with the molarity of the thiocyanate solution used to 
elute them. Pullen et al (1986) investigated the avidity of human anti-rubella antibodies 
post-vaccination in an enzyme-linked immunosorbent assay (ELISA). Using increasing 
concentrations of thiocyanate they measured resistance to elution as an indicator of 
avidity and so generated an affinity index to compare different sera. The index itself 
was defined as the concentration of thiocyanate that produced a 50% reduction in 
absorbance. Luxton and Thompson (1990) used thiocyanate elution followed by ELISA 
to look at the distribution of antibody affinity in paired serum and cerebrospinal fluid 
(CSF) samples in multiple sclerosis (MS) and viral encephalitis. Using thiocyanate 
concentrations up to 5M, at 0.5M intervals, they consistently showed that CSF IgG 
against viral antigens, (measles, herpes, varicella, rubella, toxoplasma, mumps and 
cytomegalovirus (CMV)), was of lower affinity in multiple sclerosis patients, (n=19), 
than in those patients with actual viral encephalitis, (subacute sclerosing panencephalitis 
(SSPE), n = 4; herpes simplex, n = 3 and varicella, n=3). Luxton and Thompson
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calculated their results as relative affinities using absorbance with and without 
thiocyanate (the control), expressed as a percentage. Further work by Luxton (1995) 
refined the relative affinity calculation into an affinity ratio (of high to low affinity 
antibody) to distinguish MS from encephalitis. This confirmed their previous 
observation that CSF IgG was of low affinity in MS, but of high affinity against the 
causative organism in encephalitis.
In 1988, Yeh and Krolick undertook to determine the avidities of clonotypes of IgG 
generated in experimental autoimmune myasthenia gravis by blotting focused samples 
onto antigen-coated membrane. As a method of assessing the relative avidities of the 
IgG subtypes they blotted onto nitrocellulose membranes coated with a sixteen-fold 
range of antigen concentrations. The concentration at which a band first appeared was 
used as a qualitative measure of the avidity of the band. A densitometric scan was taken 
of the results but used only to demonstrate the presence or absence of peaks.
The principle of isoelectric focusing (IEF) followed by blotting onto antigen-coated 
membrane was established by Moyle et al (1984). However, few studies incorporated 
the incubation of the focused, blotted membrane with chaotropic agents to establish the 
avidities of the antigen-specific antibodies. Marcolino et al (2000) used avidity to 
distinguish between the acute and chronic phases of toxoplasmosis. They separated a 
preparation of Toxoplasma gondii by PAGE and blotted onto nitrocellulose before 
incubating with serum samples and detecting the IgG. They probed for avidity with 6M 
and 8M urea. The avidity immunoblotting was used to confirm the results of an avidity 
ELISA whereby an avidity index was calculated based on absorbances with and without 
incubation with urea. Serum dilutions for the immunoblot were based on those that gave 
the smallest index on the ELISA. This method was also used by Nedeljkovic et al 
(2001) when investigating affinity maturation of IgG to rubella virus proteins.
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Thiocyanate elution was therefore seen as a simple and reliable method of estimating 
relative antibody avidities. When incorporated into an ELISA format the resulting data 
could be analysed quantitatively and it appeared robust enough to be used with a variety 
of antigens and antibody concentrations. In 1992, Gray and Shaw reported artefactual 
increase of bound antibody with an adaptation of the ELISA method of Pullen et al 
(1986). Finding the phenomenon in both polyclonal and monoclonal antibody 
preparations they proposed that exposure to thiocyanate induced a rearrangement in the 
primary antibody molecule that exposed more reactive epitopes to the secondary 
antibody in the assay and hence produced the artefactual increase. Their subsequent 
investigations into the possible effects of thiocyanate failed to produce any definitive 
answer; rather, they highlighted a number of possible factors involved, mainly the 
multiple binding of IgM and possible Fab reattachment at adjacent epitopes. They 
reiterated Lews (1984) work on the effect of epitope density and also proposed that 
specificity of the secondary antibody may have a part to play. McMahon and Kennedy 
(2000) reported that exposure to low pH (during affinity purification) changed a 
monoreactive to a polyreactive antibody against self-antigens, an interesting observation 
since acids can be used as chaotropes. They concluded that polyreactivity, in this case, 
was an acquired artefact after limited denaturation and not an “unmasking” of a 
physiological property of immunoglobulin. This same enhancement of antibody activity 
to both self and non-self antigens was also found by Bouvet et al (2001a) using acid 
buffer, 1.3M NaSCN and 6M urea. However, they observed that the dissociation 
constant of the IgG studied did not change after exposure to chaotrope and hence there 
was no increase of avidity. Rather, they postulated that basic polyreactive antibody 
structures were exposed by dissociating agents and could be of physiological 
significance. After rejecting the conclusions of McMahon and Kennedy (2000), Bouvet
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(2001b) further elucidated his ideas that the polyreactive autoantibodies were 
evolutionary conserved.
1.4 Intrathecal Synthesis of Immunoglobulin G
The term ‘intrathecal ‘ derives from the word ‘thecum’, which was defined as the 
cerebrospinal fluid, spinal cord and spinal roots compartmentalised by a surrounding 
membrane of dura mater (uscneurosurgery.com). In medical science, intrathecal is now 
accepted as meaning within the meninges, the three connective tissue membranes that 
enclose the brain and spinal cord, of which the dura mater forms the outer layer. Thus, 
IgG that has an intrathecal origin is synthesised within the central nervous system 
(CNS) as opposed to that of systemic origin. Normally the homogenous, polyclonal 
background seen in CSF is largely derived from serum immunoglobulins “leaking” 
across the blood-brain barrier (BBB) in low concentrations. However, when there is 
also an oligoclonal pattern an underlying pathology is likely (Figure 1.3). Oligoclonal 
bands (OCBs) are visualised in the laboratory as discrete bands clearly visible against 
the polyclonal background and are immunoglobulin secreted by a limited number of 
clones of plasma cells. Due to the low background concentration of IgG, OCBs need 
only be of a low concentration themselves to be easily visible.
Conventionally, OCB patterns are reported in five different ways (Table 1.1) including 
patterns where monoclonal IgG is detected (Andersson et al, 1994). Laboratory 
investigation of OCBs ideally requires contemporaneous serum/plasma and CSF so that 
the two can be compared with regard to any bands that are seen.
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1.4,1 Oligoclonal band patterns
Table 1.1 Oligoclonal band pattern reporting.
Pattern Abbreviation Interpretation
Negative - No bands in serum or CSF
Positive + Bands in CSF only
Mirror * Same bands in serum and
CSF
Greater than »  or > More bands in CSF than
serum
Paraprotein P Paraprotein
As reported in Neuroimmunology laboratory, National Hospital for Neurology and 
Neurosurgery (Andersson et al, 1994).
The presence of CSF OCBs of IgG indicates only that there is a humoral immune 
response. If the immune response is being conducted in the serum, then by the normal 
processes of ultrafiltration that generate CSF those bands can be seen in the CSF, 
underlining the importance of interpreting both serum and CSF together. Beyond this, 
however, OCBs are not of themselves very specific as a large number of pathologies 
result in OCBs. Anything that generates an immune response such as infection, 
inflammation and neoplasia may result in OCBs so it is important to look at their 
distribution between serum and CSF. If the OCB pattern is identical in serum and CSF 
then this indicates a systemic origin for immune activation with IgG crossing the blood- 
brain barrier easily (Thompson, 1988). In patients where there is intrathecal synthesis of 
IgG there will be OCBs either in the CSF only, or if there are OCBs in the serum, there 
will be more bands in the CSF. In the former case there is only intrathecal synthesis and 
in the latter, intrathecal synthesis occurs in addition to a systemic response.
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KEY: S =  Serum , C = C SF. The blent num ber lies a t th e  anoda l edge .
1. S erum  negative, CSF neg a tiv e  (S-, C-):
No evidence of intrathecal IgO sy n th es is  (norm al pattern).
2 . S erum  negative, CSF pas Hive (S-, C+):
O ligoclonal bands p re se n t in CSF only. Indicates in trathecal sy n th es is  of IgO.
3. S er urn p os itive, C SF p os Hive (S + , C+):
Identical pa tte rn  of bands in both se ru m  and CSF. Indicates sy s tem ic  sy n th e s is  of IgO 
"leaking" into the  CSF.
4 . S erum  positive, CSF g re a te r  (S + , C >) or (S + , C >>):
O ligoclonal bands p re se n t in both s e ru m  and CSF wHh extra bands in C SF. Indicates both 
in trathecal and  sy stem ic  IgO sy n th es is .
5 . S erum  positive, CSF positive (S m , Cm):
A bnorm al identical pattern  of bands in both se ru m  and CSF, u sually  s e e n  with a m onoclonal 
protein. Indicates peripheral IgO sy n th es is  " le ^ in g "  into the  C SF.
Figure 1.3 Oligoclonal band patterns.
Images from www.ii.bham.ac.uk/clinicalimmunology/Neuroimmunology/IEF.htm
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IEF also reveals patterns associated with monoclonal proteins. The appearance of the 
bands is very distinctive, consisting of an evenly-spaced “ladder” where the bands 
diminish in intensity towards the anode.
1.4.2 Viral encephalitis
There are a number of viruses that are more commonly neuroinvasive and neurotropic. 
Herpes simplex virus (HSV), measles, mumps, rubella, varicella-zoster, Epstein-Barr 
(EBV) (this is not a common cause of encephalitis; to the contrary, encephalitis has not 
been reported with EBV), Human herpes virus (HHV) 6 and 7 and enteroviruses are the 
commonest causes of acute encephalitis in the United Kingdom amongst individuals 
with no immune compromise (Chaudhuri and Kennedy, 2002). There are three ways 
that viruses can enter the CNS: directly through the nerves (neurally), through the nasal 
mucosa (olfactory) or via the bloodstream (haematogenously). Generally, viruses that 
cause encephalitis are common parasites of humans, so viral encephalitis is an 
uncommon complication of systemic infection. Some viruses rarely infect the CNS but 
give rise to significant pathologies when they do whereas others, such as those 
mentioned above, are common and trivial infections until they infect the CNS, when 
they become more serious.
Laboratory investigation of the CSF typically reveals a raised white cell count, with 
over 5 lymphocytes/mm3 (Davis, 2000), normal or slightly raised total protein and 
normal glucose.
1.4.2.1 Herpes simplex encephalitis
Herpes simplex encephalitis (HSE) is the most common viral encephalitis in 
immunocompetent patients and is either a primary infection, or a reactivation (Yamada 
et al, 2003) of a prior infection or reinfection (Whitley et al, 1982). It afflicts 1 to 4 per
30
million annually (Lipkin, 1997) and approximately a third of cases are in the under-20 
and half in the over-50 age groups. Mortality of untreated cases is 70% with only 2.5% 
of survivors recovering fully (Whitley and Gnann, 2002). In adults HSV2 usually 
causes genital herpes, with encephalitis being a very rare complication. Consequently, 
neonatal HSE due to HSV2 transmitted during childbirth accounts for 80% of those 
cases, but only 10% of non-neonatal cases (Aurelius et al, 1993; Dennett et al, 1997). It 
has a rapid onset with no specific clinical symptom but once a diagnosis is made, often 
on the basis of CSF polymerase chain reaction (PCR), it can be treated successfully with 
acyclovir (Chaudhuri and Kennedy, 2002). However, therapy needs to begin as soon as 
herpes simplex infection is suspected (Wutzler, 1997). This was underlined by a study 
on seven patients (Bell et al, 2003), which showed that severity of disease and survival 
in initially untreated patients was dependent on a strong intrathecal response. The virus 
is thought to spread, in reactivated form, from cranial nerve ganglia into the brain (Esiri 
and Tomlinson, 1984), which may be aided by stress, trauma and immunosuppression. 
CSF analysis may also show a high erythrocyte count, over 500 cells/mm3, if HSE is 
necrotising or haemorrhagic, and this needs to be distinguished from traumatic tap. The 
use of PCR assays for herpetic viral DNA (Rowley et al, 1990) is now a common 
method of diagnosing HSE.
1.4.2.2 Measles encephalitis
The measles virus, a ribonucleic acid (RNA) virus belonging to a subgroup of 
paramyxoviruses, enters through the upper respiratory tract and may reach the brain by 
infection of cerebral endothelial cells (Kirk et al, 1991) or circulating inflammatory 
cells (McQuaid et al, 1993). Measles virus does not appear to be spread by extracellular 
virus or cellular fusion as it is in non-neuronal cells and a trans-synaptic mechanism has 
recently been proposed (Lawrence et al, 2000).
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1.4.2.2.1 Subacute sclerosins panencevhalitis
SSPE is a rare, usually fatal, chronic CNS infection affecting less than 1 per million of 
children with measles, that occurs years after the original acute infection and is caused 
by defective measles virus (Modlin et al, 1977; Modlin et al, 1979). Measles virus is 
plentiful in brain cells of SSPE patients, who are always immunocompetent, and so is 
seen as an opportunistic infection. There are high titres of anti-measles antibodies in 
serum and CSF of SSPE patients (Connolly et al, 1967), yet this does not control the 
infection (Metha et al, 1994). Studies show the original infection was at a very young 
age, as genotypes recovered from post mortem SSPE brain corresponded to those 
present at the time of infection (Jin et al, 2001). Astrocytes, microvascular endothelial 
cells, neurons and oligodendrocytes have all been found to be infected in cases of SSPE 
(Allen et al, 1996) although there is no direct evidence of CNS involvement during the 
acute measles infection. Indirect evidence from abnormal electroencephalographs and 
CSF pleocytosis (Hanninen et al, 1980) in approximately a third of acute measles 
infections suggest that the virus may enter the CSF at this point. Rammohan et al (1982) 
reported measles infection and subsequent SSPE in a patient who had been immunised. 
They then demonstrated (Rammohan et al, 1981; 1983) in rodents that the immature 
immune system of newborns would allow persistent CNS measles infection. Studies on 
mice unable to present antigen (Urbanska et al, 1997) suggested that measles virus 
spread through neurons that were targeted by cytotoxic T lymphocytes. Raised levels of 
the antiviral type 1 IFN in SSPE CSF also suggest presence of established virus (Joncas 
et al, 1976) although wild-type measles virus has been shown to be less efficient at 
inducing type 1 IFN than vaccine strains in peripheral human lymphocytes (Naniche et 
al, 2000). Persistence in the CSF may be explained by the presence of anti-measles 
antibody keeping levels of infectious virus low. The consequence of this is that 
mutations accrue in the viral genome resulting in loss of the ability to assemble
32
infectious virus (Cattaneo et al, 1988). The subsequent accumulation of viral products 
within cells may then lead to cell death (Ikeda et al, 1995) and sometimes 
demyelination. Some demyelination may also occur due to cell-mediated mechanisms 
(Nagano et al, 1994). Although it is difficult to isolate the virus from post mortem brain 
tissue it has been successfully done and the strain was still highly neurovirulent, even in 
vitro (Ito et al, 2002).
1.4.2.3 Mumps encephalitis
Aseptic meningitis as a consequence of mumps virus infection makes up approximately 
90% of cases of acute mumps with CNS involvement (Butman, 1998). Principally an 
infection of childhood, like measles, the pathologic mechanism of mumps encephalitis 
is uncertain. Direct viral invasion can occur early in the disease whereas later, post- 
infectious encephalitis can involve autoimmune mechanisms leading to inflammation 
and demyelination.
1.4.2.4 Varicella zoster encephalitis
Infection with the exclusively human varicella-zoster virus, an a-herpes virus, usually 
leads to chickenpox (varicella), most commonly in childhood. The virus then becomes 
latent within the neurons of the cranial and spinal ganglia, occasionally reactivating as 
shingles (zoster). Very rarely does it become neuroinfectious (Barnes and Whitley, 
1986) but encephalitis following varicella-zoster infection in immunocompetent 
children has been linked with childhood stroke (Askalan et al, 2001) and cerebral 
vasculitis, which may present years after initial infection (Hausler et al, 1998).
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1.4.2.5 Rubella encephalitis
Rubella is an RNA virus of the Togaviridae family. Encephalitis is a very rare 
consequence of rubella infection with few irreversible changes and very low incidence 
of sequelae (Kenny et al, 1965). Most cases are acquired in utero leading to congenital 
rubella syndrome (CRS) and more rarely post-infectious encephalitis and progressive 
rubella panencephalitis (PRP) (Townsend et al, 1975; Frey, 1997). Only in CRS has the 
virus been demonstrated within the brain (Weil et al, 1975; Cremer et al, 1975) 
suggesting that molecular mimicry may be causing an autoimmune response in PRP.
1.4.2.6 Enterovirus encephalitis
Enteroviruses, being RNA viruses, are able to mutate rapidly and consequently can give 
rise to new diseases. Enterovirus 71 has been identified in a number of outbreaks with 
resultant paralysis (Chumakov et al, 1979) and in later Asian epidemics of the late 
1990s which resulted in deaths from encephalitis, mainly in children under five (Lum et 
al, 1998; Huang et al, 1999). Disease was spread by the enteric route and possibly by 
respiratory infection as well (Ho et al, 1999).
1.4.2.7 Human immunodeficiency virus and encephalitis
Infections with human immunodeficiency virus (HIV) type 1 can often lead to 
opportunistic infections of the CNS; neurological complications being the primary 
manifestation of acquired immune deficiency syndrome (AIDS) in 10 to 20% of cases 
(Mamidi et al, 2002). Toxoplasma gondii is an obligate intracellular protozoan that 
causes toxoplasmosis, which is generally asymptomatic. However, the loss of cellular 
immunity in AIDS can allow reactivation of latent infection (Cohen, 1999).
Up to 10% of AIDS patients will develop cryptococcal meningitis as a result of their 
illness. Cryptococcus neoformans is a fungus acquired from the environment, which
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develops a capsule in the tissues, but it has not been determined whether it is new 
infection or reactivation of latent infection when it is associated with AIDS (Mamidi et 
al, 2002). As with toxoplasmosis, the CD4+ T lymphocyte count will usually be below 
100 cells/pl before the infection becomes manifest. CMV infections of the CNS usually 
occur when the CD4+ count falls below 50 cells/pl and manifest with either dementia 
(Holland et al, 1994) or ventriculoencephalitis (Kalayjian et al, 1993).
1.4.3 Bacterial meningitis
A number of bacteria are known to cause encephalitis or meningitis. With the rise in 
HIV infection tuberculosis, and hence tuberculous meningitis, is becoming more 
prevalent. One study (Porkert et al, 1997) reported a 41% fatality rate in an American 
hospital. It is difficult to diagnose clinically, often relying on culture, which is slow and 
can be insensitive, or on histological staining, which is also insensitive (Thwaites et al, 
2002). As a consequence both dot blots (Mathai et al, 2003) and ELISA (Sada et al, 
1983) have been used for rapid detection of tuberculous meningitis.
Laboratory investigation of tuberculous meningitis shows a raised polymorphonuclear 
white cell count and reduced glucose in the CSF, possibly along with xanthochromia. 
Syphilis is another well-known disease with neurological complications, which is 
closely associated with, and exacerbated by, HIV. Historically, neurosyphilis occurred 
from between five and twenty-five years after initial infection, (being symptomatic in 
up to 9% of untreated patients, rising to 12% in patients with neurological illness with 
latent syphilis). However, according to Carmo et al (2001) neurological symptoms and 
syphilitic meningitis are most frequent within two years of infection. Laboratory 
investigation of CSF classically shows a reactive CSF-Venereal Disease Research 
Laboratory slide test (VDRL), elevated protein and pleocytosis though all may be 
normal (Tomberlin et al, 1994).
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Lyme borreliosis is caused by the spirochete, Borrelia burgdorferii, which is spread by 
tick bites. As with syphilis, approximately 10% of patients develop neuroborreliosis, 
sometimes after periods of latency. In Europe, but not the USA, where it has not been 
isolated, Borrelia garinii seems to be responsible for a higher incidence of 
neuroborreliosis due to its greater neurotropism (van Dam et al, 1993). It occasionally 
causes encephalomyelitis with a consequent intrathecal synthesis of immunoglobulin 
(Oschmann et al, 1998).
Whipple’s disease, although commonly intestinal, can both involve or be confined to 
the CNS (Anderson, 2000). The causative organism is a gram-positive bacillus, 
Tropheryma whippieii, identified in 1992 (Reiman et al). Although first described in 
1907 (Whipple), only 81 cases had been reported by 1996 (Louis et al, 1996), reflecting 
the lack of diagnostic guidelines. Since then, PCR has emerged as the most reliable 
laboratory test (Ramzan et al, 1997).
1.4.4 Multiple Sclerosis
MS is an inflammatory demyelinating disease of the CNS, more commonly found in the 
temperate regions of both northern and southern hemispheres (Rosati, 2001). At present 
the aetiology of the disease is unknown but it is thought to be mediated by an 
autoimmune mechanism and may have some genetic susceptibility (Granieri et al, 
2001).
Infectious causes of MS, often viral, have been postulated (Meinl, 1999) and a number 
of antiviral IgG responses have been found in the CSF of MS patients, particularly to 
herpes zoster, measles and rubella (MRZ reaction) and EBV (Cepok et al, 2005). 
However, they cannot be identified as any of the OCBs in the CSF of these patients and 
their low affinity towards the antigens, compared with high affinity in viral encephalitis, 
suggests they are part of a secondary, or bystander, reaction (Luxton et al, 1995). An
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investigation by Monteyne et al (1997) into HSE, using antigen blotting of OCBs, found 
low-affinity polyspecific reactions in 25% of their MS patients. A number of bacteria 
have been linked to MS and a minor fraction of OCBs have been shown to be directed 
against Escherichia coli, Enterococcus and Haemophilus influenzae (Vartdal et al,
1980). However, if any pathogen is related to MS, a well-studied topic, it remains 
unidentified (Talbot et al, 2001; Steiner et al, 2001). Molecular mimicry has been 
suggested as a possible mechanism by which infection may induce autoimmunity 
(Albert et al, 1999) and several viral and bacterial peptides have been identified that can 
activate T-cell clones specific for myelin basic protein (MBP) isolated from MS patients 
(Wucherpfennig and Strominger, 1995). Antibodies to MBP in MS patients were 
investigated by O’Connor et al (2003) using solution-phase radioimmunoassay (RIA) 
and ELISA, in this study assays of similar sensitivity. Results from both types of assay 
suggested that anti-MBP antibodies in the serum and CSF of MS patients were of low 
affinity and hence were not involved in driving any autoimmune processes. More 
recently, two bacteria have been proposed as infectious causes, Chlamydophila 
pneumoniae (Sriram et al, 1999) and Acinetobacter calcoaceticus.
1.4.4.1 Chlamydophila pneumoniae and multiple sclerosis
Chlamydophila pneumoniae is an obligate intracellular bacterial pathogen, usually of 
the respiratory tract, but essentially ubiquitous, disseminating from the respiratory tract 
within monocytes and macrophages. Although thought to be primarily a human 
pathogen, Chlamydophila bacteria have been linked to sporadic bovine 
encephalomyelitis, a chronic encephalopathy of cattle (Harshfield, 1970). Since being 
described as uniquely chlamydial in 1989, Chlamydophila pneumoniae has also been 
linked with other chronic conditions such as atherosclerosis and Alzheimers disease 
(Swanborg et al, 2003).
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A study by Sriram et al (1999) reported the presence of Chlamydophila pneumoniae in 
the CSF of MS patients by culture and PCR at significantly higher levels than in 
controls, with the conclusion that Chlamydophila pneumoniae could be the infectious 
cause of MS. These findings prompted a number of studies, the results of which have 
been collated by Furrows et al (2003), who used PCR and CSF culture to try and 
replicate Sriram’s findings. However, they could not find any association between 
Chlamydophila pneumoniae infection and MS. Sriram’s original study did not 
investigate the serology of either MS patients or controls, unlike some later studies 
(Boman et a\, 2000; Derfuss et al, 2001). Both of these found over half of their control 
and MS cohorts to be positive for Chlamydophila pneumoniae whilst PCR on the 
corresponding CSF samples yielded no positives at all. CSF cultures in Boman’s study 
were also completely negative unlike Hao et al (2002) who did find one positive in each 
cohort and more positive PCR results in MS and controls but these were not significant 
and had a far lower incidence than in serum. Kaufman et al (2002) split CSF samples 
and sent them to four different laboratories for PCR detection of Chlamydophila 
pneumoniae. Of the four, one reported 73% of MS and 23% of controls as positive. The 
other three reported all samples as negative, leading the authors to the conclusion that 
variation in techniques could account for the different results.
A further study by Vojdani et al (2002) attempted to explain a possible cause of autism 
as exposure to Chlamydophila pneumoniae generating serum antibodies that cross­
reacted with a variety of neuron-specific antigens. Although the authors claimed that 
autistic children showed higher levels of IgG, IgA and IgM against a variety of neuron- 
specific proteins, including MBP, they did not demonstrate any specificity for any of the 
nine neuronal antigens tested; rather patients had apparently higher levels of antibody to 
all of them. The same effect was shown with the non-neural antigens, butyrophilin from 
milk, Chlamydophila pneumoniae peptide 483 and streptococcal M protein, possibly
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reflecting an inappropriate sample dilution, lack of measurement or correction of serum 
IgG or any combination of the above. Crucially, it was not possible to obtain CSF 
samples, even though the antibody effects must have been within the CNS, nor was 
blood-brain barrier function assessed.
A prospective study (Munger et al, 2004) covering two large cohorts in the USA, of 
three million USA Army personnel and over 120 000 from a Medical Care Program, 
measured serum IgG and IgM by microimmunofluorescence (MIF) in samples taken 
prior to onset of MS. They found 83 and 46 cases of MS respectively, but could not find 
any link between seropositivity or antibody titres and risk of developing MS, except a 
slightly increased risk in the smaller cohort. As a result, the authors concluded that 
although seropositivity and antibody titres could not predict risk of developing MS, they 
could not say that previous infection with Chlamydophila pneumoniae did not alter the 
risk of developing MS.
1.4.4.2 Acinetobacter and multiple sclerosis
Acinetobacter sp. are commonly found in soil and water and are often part of the 
commensal flora of man and animals. They are implicated in many nosocomial 
infections, including secondary meningitis, but are most commonly seen in nosocomial 
pneumonia in ventilated patients on intensive treatment units (Bergogne-Berezin and 
Towner, 1996). An amino acid sequence homology was found between the enzyme, 4- 
carboxymuconolactone decarboxylase (4-CMLD), present in Acinetobacter 
calcoaceticus 23055 (Ebringer et al, 1997) and a sequence of MBP (amino acid residues 
110-124), encephalitogenic in guinea pigs (Eylar et al, 1970). The same sequence was 
also found in the y-isoform of the enzyme, y-CMLD, in Pseudomonas aeruginosa 
(Hughes et al, 2001). This same study investigated serum antibodies against five strains 
of Acinetobacter (including Acinetobacter calcoaceticus), Pseudomonas aeruginosa
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and Escherichia coli as a control organism on the basis that it contains the amino acid 
sequence under investigation but in a different enzyme (www.ebi.ac.uk). The authors 
demonstrated elevated levels of serum IgG, IgM and IgA against all five Acinetobacter 
strains and Pseudomonas aeruginosa, but not Escherichia coli, in MS patients but not in 
healthy controls. Raised antibody titres were also found against MBP and 
neurofilaments in the MS patients but not the controls. Using the absorbance values 
from the ELISAs for the IgG assays for MBP, Acinetobacter and neurofilaments an 
index was developed to try to distinguish MS from the controls.
Using recombinant peptide Hughes et al (2003) showed increased serum IgA, IgM and 
IgG to a peptide containing the common sequence between Acinetobacter calcoaceticus 
4-CMLD and MBP. They also found a sequence homology between subunit A of 3- 
oxoadipate CoA transferase in Acinetobacter sp. and myelin oligodendrocyte 
glycoprotein (MOG) and showed increased levels of serum IgA, IgG and IgM against a 
recombinant peptide containing the sequence in MS patients. The study was controlled 
with healthy patients and patients with cerebrovascular accident (CVA).
Acinetobacter sp. had previously been proposed as the causative agent of bovine 
spongiform encephalopathy, (BSE), (Ebringer et al, 1997). The proposed mechanism 
was by molecular mimicry, based on evidence presented later (Hughes et al, 2001) as a 
possible cause of MS. Further work by the same group (Tiwana et al, 1999) found 
serum autoantibodies of IgA type that cross-reacted with sequences in Acinetobacter 
calcoaceticus, bovine neurofilaments and myelin. On this basis they developed an 
ELISA that used the antibody response to Acinetobacter calcoaceticus as an indirect 
means of detecting BSE in live animals (Wilson et al, 2003). The theory was not widely 
accepted and in 2002 Nielsen et al tested a wide variety of animals infected with 
transmissible spongiform encephalopathies (TSEs) as well as non-infected controls 
using an assay including both whole cell and lipopolysaccharide from Acinetobacter sp.
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in an ELISA format. They failed to find significantly raised levels of IgA against 
Acinetobacter calcoaceticus which, taken with varying normal levels of antibodies to 
Acinetobacter sp., resulted in “considerable overlap” between infected and non-infected 
populations. Nor could they find significance in measuring antibodies to MBP or 
looking for polyreactive antibodies, tested by absorption with Brucellosis abortis.
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1.5 Introduction to Methods
1.5.1 Isoelectric focusing
Proteins are made up of amino acids that have carboxylic side-groups and amino, 
imidazole and guanidine side-chains. When the pH is low, carboxylic side-groups are 
neutral:
R-COO' + H+ —> R-COOH 
and at high pH they are negative:
R-COOH + OH' R-COO' + H20  
Amino, imidazole and guanidine side-chains are positive at low pH:
R-NH2 + H+ -> R-NH3+
and neutral at high pH:
R-NH3‘ + OH' — R-NH2 + H20  
Glycosylation and phosphorylation will also influence net charge.
Thus for any protein molecule there is a pH at which it will have a net charge of zero. 
This is called the isoelectric point (pi) and is the fundamental principle on which the 
technique of IEF is based. A mixture of proteins, such as serum or CSF, is 
electrophoresed on a gel, usually agarose, containing molecules called ampholytes. 
These are usually synthetic polymers based on repeating amino acids of gradually 
increasing size, which therefore have a wide range of pis. When they are subjected to an 
electric current these ampholytes will move through the gel, the positively charged to 
the anode and the negatively charged to the cathode. Ampholytes with the lowest pi 
migrate to the anode and those with the highest pi to the cathode whilst the intermediate 
ampholytes migrate to the points in between, so determining the pH and hence a smooth 
pH gradient. Although ampholytes have a high rate of diffusion owing to their small 
size, they will diffuse away from their pi and return electrophoretically ensuring the
42
gradient remains smooth. IEF is best run at a constant temperature of approximately 
10°C (Westermeier, 2001).
1,5.2 Principle o f Eastern Blotting
Eastern blotting (EB) investigates antibodies in a sample using their affinities for 
antigen. The initial separation of the antibodies in the sample is by IEF. The antibodies 
are then transferred to a membrane impregnated with the antigen(s) of interest by 
pressure blotting (Figure 1.4). Antibodies with any affinity towards the antigen(s) are 
retained on the membrane until it is subsequently incubated with various concentrations 
of chaotrope. The remaining antibody on the membrane is then detected with a double­
antibody system. The resulting patterns can be interpreted visually or quantified using 
densitometry.
1.5.2.1 History o f Eastern Blotting
A variety of methods routinely available in the early 1980s, such as complement 
fixation, were capable of showing that an immune response had been raised against a 
particular pathogen but did not have the specificity to show the clonality of the 
response, i.e. whether it was a polyclonal, oligoclonal or even monoclonal response.
The technique of immunoblotting was developed (Moyle et al, 1984) to investigate 
viral-specific oligoclonal IgG and was largely based on the method of IEF of Walker et 
al (1983). Moyle et al (1984) used crude viral antigen, from infected cell culture, to 
impregnate nitrocellulose membrane, which was then laid over a gel containing samples 
focused by IEF. As the sample proteins were transferred to the membrane by passive 
blotting, the antibodies with specificity for the viral antigens would recognise and bind
43
with the antigens in the membrane. These antibodies could then be detected 
immunologically. This approach meant that all antibodies raised in the subject against 
the infective agent could potentially be detected in the assay and also negated the need 
to concentrate CSF prior to electrophoresis which can give rise to artefacts (Hershey 
and Trotter, 1980).
This original work looked at oligoclonal IgG in the CSF raised against a measles 
glycoprotein in patients with SSPE, a measles infection of the CNS, and was negatively 
controlled with CSF from patients with other inflammatory neurological conditions. 
Moyle and Thompson (1985a) expanded on this study to investigate restriction in the 
light chain “specificity for antigen” of the specific IgG in SSPE but found that there was 
no dominant type. They then looked at HSE (Moyle and Thompson, 1985b) using the 
immunoblotting technique to demonstrate intrathecal synthesis of specific IgG. 
Inflammatory diseases of the CNS can impair blood-brain barrier function allowing 
antibodies to cross into the CSF from the serum. It is therefore important to be able to 
distinguish intrathecal and systemic humoral immune responses by assaying paired CSF 
and serum from the patient. The method proved capable of showing that IgG specific 
for herpes simplex was being synthesised intrathecally and did not come from a serum 
response.
Thus far, all the work on antigen immunoblotting had been done using nitrocellulose 
membranes. Nespolo et al (1987) found that polyvinyldifluoride (PVDF) membranes, 
thicker and stronger than nitrocellulose, gave greatly enhanced sensitivity for protein 
detection. Although binding lower amounts of protein than nitrocellulose, the higher 
retention capacity for the protein molecules bound to the membrane surface produced 
the effect. Luxton and Thompson (1989) explored the use of PVDF in antigen 
immunoblotting, coating the membrane with a variety of antigens and using random 
paired serum and CSF samples positive for oligoclonal IgG by IEF. They concurred that
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patterns on PVDF were more intense but also found that some samples had different 
band patterns on the reverse side of the membrane and on a second membrane. 
Polyclonal background IgG was only found on the obverse side of the first (coated) 
membrane. They postulated that this phenomenon was due to the differing affinities of 
the oligoclonal IgG bands for the antigen; the higher the affinity the quicker the 
antibody binds whilst lower affinity clones will pass into the membrane and onto the 
reverse side. Alterations in the amount of antigen loaded onto the membrane seemed to 
confirm this, less antigen resulting in a less intense pattern on the obverse.
Antigen immunoblotting was employed by Mavra et al (1992) as part of their strategy 
to look at specificity of IgG paraproteins against a range of neurotropic agents. On a 
qualitative ELISA screening technique thirteen of thirty-four patients with paraprotein 
bands on IEF were positive for at least one antigen, after immunoblotting only one 
patient was positive showing that antigen immunoblotting can be a very discriminating 
test. Monteyne et al (1997) conducted a study comparing detection of intrathecal 
synthesis of anti-herpes simplex IgG by antigen-mediated immunoblotting and 
calculation of antibody index following ELISA techniques. Twenty-seven paired 
samples from fifteen patients diagnosed by CSF PCR were compared to MS patients 
acting as controls. Both methods detected 14/15 HSE patients, the exception being a 
patient with relatively benign HSV type 2 encephalitis, which the authors ascribed to 
either reduced sensitivity of the assays with regard to type 2 HSV, low viral load or 
false negative.
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Figure 1.4 Schematic diagram of Eastern blotting.
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1.6 Covalent binding membrane
For the work, Ultrabind™ US450 membrane was used, which is a patented (USA 
patents 4961852 and 4824870) covalent binding affinity membrane (Pall). The 
membrane is made o f modified polyethersulphone and contains aldehyde groups which 
bind any molecule containing a primary amine (see Figure 1.5). The membrane has a 
pore size o f 0.45 pm, the same as the nitrocellulose membrane routinely used in the 
laboratory, and an IgG binding capacity o f 135 pg/cm2, superior to that o f nitrocellulose 
(80 pg/cm2).
R
H o  N
+  R — N
\  / f  H
C _ /  C - H +  H20
1 H 1
R R
PES PES
Figure 1.5 Binding of antigen to Ultrabind membrane via amide linkage.
Key: PES, polyethersulphone membrane (Ultrabind); RCOH, aldehyde group on 
Ultrabind membrane; RNFh, primary amine group on antigen.
1.7 Western blotting
Western blotting, also known as Western transfer is a technique used for separating 
proteins in a mixture and then transferring them onto a membrane for any further 
investigations. The proteins are separated on the basis o f their molecular weights by 
electrophoresis in a polyacrylamide gel (PAGE), and are then electrophoretically blotted 
from the gel onto the membrane.
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1.8 Quantification of bands by densitometry
Densitometry is a form of photometry used to measure electrophoresis lanes. It can be 
used to measure transmittance or reflectance of light, for clear and opaque media 
respectively, to produce a densitogram, also called a peak diagram. The area(s) under 
the peak(s) can then be quantified using a variety of software programs available. 
Densitometric scanning is most commonly used to quantify serum protein fractions after 
electrophoresis; the percentage values from the densitometry being used to calculate 
actual values from total protein estimation. It can also be applied to IEF patterns (Paluch 
et al, 1984).
1.9 Total protein estimation
The assay used to measure total protein was the Bio-Rad DC Protein Assay (Bio-Rad), 
which detects protein colorimetrically following solubilisation in detergent. The assay 
consists of two stages; firstly, protein reacts with copper in an alkaline medium 
(tartrate), secondly, the copper-treated protein reduces Folin reagent by removing one, 
two or three oxygen atoms. This results in reduced species of a blue colour, the 
absorbances of which can then be read and used to calculate concentration.
1.10 Rocket electrophoresis
Samples are added to cylindrical wells cut into an electrophoresis gel containing 
antibodies to the protein to be measured. When electrophoresed the sample protein of 
interest will migrate through the gel and react with the antiserum, forming an insoluble 
complex, which therefore precipitates. As the serum antigen is depleted the line of 
precipitation tapers to a point and the length of the resulting “rocket” is proportional to 
the concentration of the antigen in the sample. The presence of polyethylene glycol
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(PEG) promotes precipitation of the immune complex by competing for water of 
solvation with the immune complex.
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2.0 Methods
2.1 Isoelectric focusing
2.1.1 Isoelectric focusing gel manufacture
A 22.6cm x 11.5cm gel was made by adding 0.3 g of IEF agarose (Amersham 
Pharmacia) to 30ml of deionised water in a glass bottle with a screw cap. The cap was 
lightly screwed on because the bottle was then placed in a boiling water bath until the 
agarose was fully dissolved. Some methods include 3.6 g sorbitol and 3 ml glycerol in 
the gel mixture but these are not absolutely necessary. Both were originally included in 
gel recipes to minimise diffusion of bands when the gel itself was stained for 
interpretation. Thus, the gels were made using just 30 ml of deionised water with 0.3 g 
IEF agarose. The molten gel was then transferred, still in the bottle, to a water bath at 65 
°C and given at least one hour to equilibrate to the lower temperature.
Whilst the gel was cooling a casting frame was constructed. A sheet of GelBond (Serva) 
was cut to 25 cm x 13.5 cm, the same dimensions as a glass plate, 3 mm thick. A small 
pool of 50% methanol (Hayman): 50% water mixture was squirted into the centre of the 
glass plate and the GelBond fitted squarely on it. Both sides of the GelBond are 
hydrophilic.
Once the GelBond was on the glass plate, a length of paper towel was placed across the 
top and the excess methanol: water squeezed out using a photographic print roller. A 
plastic template (Amersham Pharmacia) was laid on the GelBond, smooth side down to 
ensure best contact, and the whole apparatus secured using bulldog clips. Once it was 
determined, by spirit level, that the gel casting apparatus was level, it was heated using 
a hairdryer.
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Two ml of pH 3-10 and 0.5 ml pH 8-10.5 ampholyte solutions (Amersham Pharmacia) 
were added to the molten gel, using a syringe (Becton Dickinson). The ampholytes were 
mixed into the molten gel by swirling the bottle, after which the bottle was recapped, 
and returned to the water bath briefly to regain temperature.
When the plate was warmed, the hairdryer was switched off and the bottle of molten gel 
was taken from the water bath. The gel was poured carefully into the casting frame 
where the neck of the bottle was used to ensure the gel was evenly spread within the 
whole frame and that any air bubbles were moved to the edges of the frame. The gel 
was allowed to cool and set before removal of the bulldog clips and transfer of the gel in 
the frame to a plastic, lidded box containing a damp paper towel. The gel could then be 
stored in the damp box at 4 °C for up to a week before use.
2.7.2 Running the gel
The prepared gel (see section 2.1.1) was taken out of the cold room, still in the damp 
box, and allowed to equilibrate to ambient temperature. The electrophoresis tank 
(Amersham Pharmacia) on which the blot was run was coupled to a circulating water 
cooler (Amersham Pharmacia) set at 12 °C. It was necessary to start the cooler at least 
30 minutes before the scheduled beginning of the run to ensure that the plate of the tank 
was at a constant temperature.
Whilst the gel was equilibrating the wicks were put in to soak. These were strips of 
blotting paper (Hollingsworth and Vose), cut to slightly less than the length of the gel 
(22 cm) and approximately 6 mm wide. Three of these, laid on top of each other, 
formed one wick. Two wicks were soaked, one in 0.05M sulphuric acid and the other in 
1M sodium hydroxide.
The gel was taken from the damp box, lifted away from the glass plate and carefully 
separated from the casting frame. Approximately 1 ml of 50% methanol: 50% water
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mixture was squirted onto the centre of the cooling plate and the gel, on the GelBond, 
was laid squarely onto the cooling plate, the methanol: water providing an airtight seal 
between the GelBond and the cooling plate. Any excess methanol: water leaking out 
from the edges of the gel and onto the GelBond was dried away with a tissue. Using a 
scalpel blade the four sides of the gel were trimmed by approximately 2 mm. This 
removed the slightly raised edges, which result from the casting, best described as a 
“meniscus” effect, which may potentially affect the contact of the wicks and 
“soakaways”, to be mentioned later. Once the gel was trimmed it was blotted three 
times with nitrocellulose membrane, cut to 20 cm x 10 cm, to remove excessive 
moisture from the surface of the gel. The membranes were left on the gel until they 
were soaked through and were then removed. Next, an application foil (Amersham 
Pharmacia, discontinued) was laid on the gel, approximately 3 cm up from the bottom 
edge of the gel, i.e. the edge nearest the experimenter, and central with regard to the 
vertical edges of the gel.
The application foil was then pressed gently but firmly onto the gel to ensure that it 
made an airtight seal. If the seal is not airtight, when the samples are applied they may 
be drawn away from the well by capillary action resulting in smeared and indistinct 
patterns that are difficult to interpret.
Samples were then applied, from right to left, leaving the outside wells either unused or 
containing distilled water. When affinity studies are being done that require the 
membrane to be divided after blotting, marks can be made with waterproof ink on the 
upper and lower edges of the GelBond, which lay outside the cast gel, corresponding to 
where the division will be.
The wicks were first blotted in paper tissue and then placed on the gel; the sulphuric 
acid-soaked wick at the anode and the sodium hydroxide-soaked wick at the cathode. 
The anodal wick should not touch the application foil and the cathodal wick should be
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placed at least 1 cm in from the top of the gel. Once the wicks were in place paper 
towels were placed at the anodal and cathodal edges of the gel, though not touching the 
wicks, to absorb the moisture generated as the gel was run.
The electrodes on the glass plate were adjusted so that the wire ran along the centre of 
the wick. The electrodes were secured in position using their integral screw clamps and 
the plate placed in position using the feet at the comers fitted into the appropriate holes 
in the tank. The leads from the electrodes were connected and the lid of the apparatus 
put on. The lid was connected to the power supply (EPS 3501, Amersham) and the gel 
is run at 900 volts, maximum 150 watts and 20 mA for 900 volt hours.
During the early part of the run, somewhere between 200 and 400 volt hours, runs were 
paused to allow the soakaways to be replaced, the application foil to be removed and 
cleaned and excess moisture to be blotted from the wicks. The electrode plate was then 
replaced and reconnected and the run continued until completion.
2.1.3 Blotting the gel
Once the gel had finished running the electrophoresis tank lid and the electrodes were 
removed to expose the gel. Firstly, the soakaways were removed, and then the wicks 
were taken off, all being discarded. A piece of nitrocellulose (BioRad), approximately 
10 cm x 20 cm, was laid on the gel for about thirty seconds to remove any moisture and 
protein lying on the surface of the gel. The membrane impregnated with the protein(s) 
of interest was then carefully laid on the gel ensuring that there was no air trapped 
underneath it. If air does become trapped then the bubbles can be squeezed out using a 
glass rod rolled gently but firmly from the centre of the membrane to the edge.
Once the membrane was in place six pieces of blotting paper were placed on top 
followed by a glass plate and a 1 kg weight. This was left in place for ten minutes. The 
apparatus was then dismantled and the membrane taken for further experimentation.
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2.1.4 Incubating with sodium thiocyanate solutions
For affinity studies using NaSCN (Sigma) the membrane was left on the gel after the 
weight, glass plate and filter paper had been taken off. Whilst still in situ the blotted 
membrane was cut, using a surgical blade and true-edged ruler, using the marks in 
waterproof ink made on the edge of the GelBond when the samples were applied (see 
Section 2.1.2). The pieces of membrane were then labelled appropriately and incubated 
with NaSCN solution in a tray, 10 cm x 10 cm, (Elkay) for the required length of time. 
Once the incubation was finished the membranes were washed in twenty rapid changes 
of running tap water to remove any NaSCN from the experiment prior to being 
developed.
2.1.5 Development o f the membrane
Membranes that had been incubated with NaSCN were reincubated in blocking solution 
(see section 2.2.1) for at least thirty minutes to ensure that any blocking protein that 
may have been stripped by incubation with NaSCN was replaced, prior to incubation 
with the first antibody.
The membranes, measuring approximately 10 cm by 5 cm, were incubated in first 
antibody, appropriately diluted, and were incubated overnight on a slow rocker (Stuart 
Scientific) at 4 °C. The following morning the membranes were brought back to room 
temperature on a slow rocker before the antibody solution was decanted off. Each 
membrane was then washed in five changes of 25 ml of 0.025% Tween 20 (Sigma) in 
0.2% skimmed milk/0.9% saline, changed every ten minutes. Membranes were then 
incubated in secondary antibody, appropriately diluted, for two hours at room 
temperature on a slow rocker. The secondary antibody was decanted off and the 
membranes washed in distilled water. The membranes were then kept in saline until the 
colour reagent was ready.
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2.2 Coating membranes
2.2.1 Coating the membrane with human serum albumin
A solution of human serum albumin (HSA) (Sigma) was made by dissolving 2.5 g of 
HSA in 100 ml of deionised water to give a stock solution of final concentration of 25 
g/i-
Ultrabind US450 (Gelman) membranes, cut to 10 cm x 20 cm on a guillotine, were 
placed in a dry polypropylene incubation chamber and soaked through with 25 ml of 
0.9% saline. 400 pi of the stock solution of HSA was mixed into a further 25 ml of 
saline and added to the membrane in the incubation chamber. Thus, the final amount of 
HSA in the incubation chamber was 1000 pg, or 1 mg. The membrane, 200 square 
centimetres, is theoretically coated with 5 pg of HSA per square centimetre. Ultrabind 
450 has a quoted total binding capacity of 135 pg per square centimetre; thus it is bound 
at 3.7% of total binding capacity.
Once the membrane was incubating in the antigen solution, the lid was placed on the 
incubation chamber and the whole was transferred to a slow rocker at 4 °C overnight. 
The following morning the incubation chamber and its contents were allowed to return 
to ambient temperature, on a slow rocker, before the antigen solution was decanted. The 
membrane, still in the incubation chamber and on the rocker, was washed twice for ten 
minutes in tap water. This removed weakly bound protein from the membrane. Once the 
tap water had been decanted the membrane was blocked. The blocking solution was 2% 
milk in saline i.e. 2 g of dried skimmed milk powder (Marvel) dissolved in 100 ml of 
saline with 1% Tris (Sigma).
The membrane was blocked for at least one hour, although it could have been left 
longer, before the blocking solution was decanted and the membrane washed twice in 
cold tap water. The membrane was transferred, using clean forceps, onto a piece of
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blotting paper where it was allowed to air dry before being put between two clean 
pieces of blotting paper and stored in a sealed plastic bag at -20 °C. Membranes kept 
this way have been stored for up to a week before use with no discernible deterioration 
in the final blot.
2,2,2 Coating a membrane with bacterial and viral proteins
2.2.2.1 Preparation o f bacterial cultures
The primary culture of Acinetobacter calcoaceticus (NCIMB 16904) was obtained from 
the National Collections of Industrial and Murine Bacteria Ltd. (Aberdeen, Scotland). 
The Department of Microbiology at King’s College, London provided primary cultures 
for Pseudomonas aeruginosa, Proteus mirabilis and Escherichia coli.
The cultures were grown in one litre flasks on an orbital shaker for two days at 30 °C 
for Acinetobacter calcoaceticus and at 37 °C for Pseudomonas aeruginosa, Proteus 
mirabilis and Escherichia coli in 200 ml nutrient broth (Oxoid: 25 g/1). Flasks were 
inoculated with two loopfuls of starter culture and left shaking for 6 hours at 37 °C. 
Batch culture cells were harvested by centrifugation at 4000 rpm for 20 minutes at less 
than 10 °C (Beckman JA-20 rotor 6 x 250ml). Pellets of cells were completely 
resuspended in BugBuster (Novagen) (3 ml/50 ml nutrient broth) and incubated on a 
shaking platform for 20 minutes at room temperature.
The lysed bacterial culture was diluted 3:1 with 80 mg/ml sodium dodecyl sulphate 
(SDS) (BDH) solution and 0.5M dithiothreitol (DTT aka Clelands reagent) (Sigma) 
added at 1 /20th of the original volume of culture and SDS. The container was then 
sealed and placed in a 65 °C bath for fifteen minutes.
Prior to use the total protein of the bacterial preparation was determined using a 
modified Lowry method (Lowry et al, 1951) (see Section 2.6).
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2.2.2.2 Coating the membrane with bacterial antigens
Ultrabind US450 membranes (Gelman), cut to 10 cm x 20 cm, were placed in an 
incubation chamber and allowed to soak thoroughly in 25 ml of ImM 
ethylenediaminetetra-acetic acid (EDTA) (BDH)/0.9% saline. The processed bacterial 
antigen was mixed into a further 25 ml of ImM EDTA/0.9% saline and added to the 
incubation chamber at sufficient volume to coat the membrane at 5 pg per square 
centimetre. The sealed chamber was incubated overnight at 4 °C on a slow rocker. After 
returning to room temperature the antigen solution was decanted off and the membrane 
washed in two changes of tap water. Available protein binding sites were blocked with 
ImM EDTA/2% w/v skimmed milk/0.1% Tween/0.9% saline for two hours. Once 
blocked, the membrane was rinsed in tap water and left to air-dry between two sheets of 
blotting paper before being placed in fresh blotting paper and stored in a sealed plastic 
bag at -20 °C. Membranes could be stored for up to one week with no visible 
deterioration on the final blot.
2.2.2.3 Coating the membrane with commercial virus preparations
Measles and Herpes antigens: the antigen was supplied freeze-dried (Quadratech) and 
reconstituted in 1 ml of ultrapure distilled water. Total protein was estimated using the 
Lowry method. Membranes were coated at 50 pg total protein per square centimetre of 
membrane by mixing the appropriate quantity of reconstituted antigen into 25 ml of 
saline. This was immediately added to a membrane already soaking in 25 ml saline in 
an incubation chamber, which was then sealed and incubated overnight on a slow rocker 
at 4 °C. The following morning the membrane was briefly rinsed in tap water and 
blocked in 2% w/v skimmed milk/1% w/v Tris in 0.9% saline for at least one hour.
After blocking, the membrane was rinsed in tap water and left to air dry before being 
stored as above (see Section 2.2.2.2).
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2.3 Western blotting for Chlamydophila pneumoniae
Lithium dodecyl sulphate (LDS) (Invitrogen) sample buffer was used rather than the 
sodium dodecyl sulphate (SDS), as LDS remains soluble for longer thus enabling 
antigen preparations to be stored for longer. Also, denaturation of proteins with LDS 
can be successfully done at 65 °C as opposed to 100 °C with SDS, which thus prevents 
some loss of labile proteins. DTT (Invitrogen) was also added to prevent the formation 
of disulphide bonds between cysteine residues.
2.3.1 Preparation of Chlamydophila antigen for Western Blotting
The cell pellets, control and infected, were washed. 1 ml of saline was added to the 
pellets and the bottle gently shaken by hand to dislodge the cells. They were then 
centrifuged at 4000 rpm and the supernatant removed. This was repeated twice more. 
Pellets were then suspended in 300 pi each of T-Per (Pierce) and BugBuster (Novagen) 
and incubated at 56 °C for 25 minutes before being frozen at -80 °C.
2.3.3 Western blot
The desired dilution of antigen preparation was determined by serially diluting the 
antigen preparation (1/2, 1/4,1/8, 1/16 and 1/32) in dilute LDS solution (1 part LDS to 
3 parts deionised water). 25 pi of each dilution was electrophoresed on a NuPage 4-12% 
Bis/Tris 10 well precast gel (Invitrogen) at 200 V, 120 mA and 25 W for 35 minutes in 
a buffer tank with electrode and power pack (Invitrogen) in 2-[N- 
Morpholinojethanesulphonic acid (MES) running buffer (Invitrogen). The gel was 
transferred to fixative solution and was then stained with Coomassie Brilliant Blue 
(Invitrogen) to visualise the protein bands present for assessment of optimum dilution in 
the subsequent Western blotting.
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Cell line homogenates were prepared by adding 40 pi of homogenate, 50 pi of LDS, 20 
pi of 0.5M DTT (to a final concentration of 0.05M) and 90 pi of deionised water, thus 
giving a final dilution of approximately 1 in 5 for the antigen preparation and 1 in 4 for 
the LDS. The preparation was then incubated at 65 °C in a preheated water bath (Grant) 
for 15 minutes in a snap-top vial (Eppendorf). Homogenates were cooled at ambient 
temperature and mixed on a vortex mixer (Stuart Scientific).
The 220 pi of antigen preparation was applied to the large well of a NuPage 4-12% 
Bis/Tris 2D gel (Invitrogen) with 3 pi of SeeBlue Plus molecular weight marker 
(Invitrogen) in the small well and run as for the serial dilutions (above). The gel was 
electroblotted to transfer the proteins onto a Biodyne membrane (Gelman) for 
subsequent investigations. Western transfer was carried out using a semi-dry 
electroblotting system (Invitrogen) with transfer buffer (Invitrogen).
The electrophoresed gel was removed from its plastic cassette by breaking off the back 
of the cassette and applying a piece of filter paper, 9 cm , soaked in transfer buffer. The 
gel was then eased away from the front piece of the cassette by adhering to the filter 
paper. This was then placed into the bottom of the blotting cassette, containing the 
cathode electrode, which contained two buffer reservoirs, 9 cm , and three pieces of 
filter paper, all soaked in transfer buffer. A piece of Biodyne, 9 cm x 9 cm, soaked in 
transfer buffer, was then laid onto the gel; any air bubbles between them were gently 
squeezed out to the edge of the membrane. Two more pieces of soaked filter paper were 
laid on top, followed by a piece of porous cellophane (Amersham Pharmacia), 9 cm 
square, soaked in transfer buffer, four more pieces of soaked filter paper and two more 
buffer reservoirs. This “sandwich” was then repeated, thus allowing two gels to be 
blotted simultaneously. The top of the blotting cassette, containing the anode, was put 
on the top and the complete cassette inserted into the electrophoresis tank. The 
electrophoresis tank was filled with tap water to surround the blotting cassette and
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provide a medium for heat exchange to remove the heat generated by the transfer 
process. Electroblotting was for one hour at 25 V, 160 mA and 17 W at room 
temperature.
Once blotted, the membrane was removed from the blotting cassette and placed into a 
blocking solution of 2% w/v skimmed milk powder in 0.9% saline on a slow rocker for 
at least one hour. This was to block any unbound protein binding sites with milk protein 
and hence reduce background when the membrane was finally developed and 
visualised. The blocking solution was rinsed off with two changes of 0.9% saline. 
Membranes were then either dried at room temperature between two pieces of filter 
paper and stored at -20 °C in a sealed plastic bag, or used immediately. Membranes 
stored were always used within one week of preparation without any noticeable 
deterioration in quality when compared to fresh membranes.
2.3.4 Probing of membrane
The blotted and blocked membrane was then placed into a ten-lane incubation manifold 
(Hoefer) and 2 ml of the diluted serum samples were applied. Serum samples were 
diluted 1:100 in 0.2% w/v skimmed milk in 0.9% saline by adding 50 pi of vortex 
mixed serum to 5 ml of the diluent. The loaded manifold was left to incubate overnight 
at 4 °C on a slow rocker. The following morning the manifold was allowed to 
equilibrate to room temperature on a slow rocker before being washed. 2 ml of wash 
solution (0.9% saline/0.2% w/v skimmed milk/0.05% Tween 20) was applied to each 
lane for ten minutes on the slow rocker. This was repeated ten times. The membrane 
was then removed from the manifold and incubated with 25 ml of rabbit anti-human 
IgG, IgM, IgA, k  light chain and X light chain conjugated to HRP (Dako), diluted 
1/1000 in 0.9% saline/0.2% w/v skimmed milk for one hour at room temperature on a 
slow rocker. The membrane was then washed ten times in 25 ml of wash solution before
60
being transferred into saline prior to visualisation with enhanced chemiluminescence 
(ECL).
2.3.4.1 Enhanced chemiluminescence
This procedure was performed in its entirety in a darkroom under safelight.
The membrane was taken out of saline and placed on a sheet of blotting paper to remove 
excess saline. 5 ml each of SuperSignal® West Pico Luminol enhancer solution and 
SuperSignal® West Pico stable peroxide solution (both Pierce) were mixed in a plastic 
boat, 10 cm by 10 cm. The membrane was immersed in the luminol/peroxide solution 
for five minutes with occasional agitation by hand to prevent product accumulation. The 
membrane was then taken out of the luminol/peroxide solution and placed on blotting 
paper to remove the excess luminol/peroxide solution before it was sandwiched between 
two sheets of clear acetate. The “sandwich” was constructed in a Hypercassette™ 
(Amersham), a light-proof lidded box. Under safelight a sheet of chemiluminescence 
film (Hyperfilm™, Amersham Pharmacia) was placed over the blot(s) and the lid of the 
box closed and sealed. After exposure, the film was removed from the Hypercassette™ 
and developed automatically in an X-OMAT Multiloader 300 (Kodak).
2.4 Other methods used in Chlamydophila pneumoniae in MS study
The author did not perform the assays detailed in sections 2.4.1, 2.4.1.1, 2.4.2 and 2.4.3.
2.4.1 Culture of Chlamydophila pneumoniae from cerebrospinalfluid
The culture method was based on that used by Sriram et al (1999), with some 
modifications. HL and Hep2 cell lines were used for culture (Kuo and Grayston, 1990; 
Roblin et al, 1992). Approximately 400 pi of CSF was collected directly into 1.5 ml
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microcentrifiige tubes. Trypsin 0.25%/EDTA ImM (Gibco BRL) was added to a final 
concentration of 0.1% trypsin. The sample was vortex mixed, incubated at 35 °C for 30 
minutes, then mixed again and centrifuged at 13,000 rpm for 45 minutes. The 
supernatant was discarded and the pellet resuspended in 1 ml Eagles growth medium 
(GibcoBRL) with 10% fetal calf serum (Globepharm) and added bicarbonate, glutamine 
and vitamins. The resuspended sample was divided between 2 HL and 2 Hep2 
monolayers. The monolayers had been prepared in advance on coverslips, washed with 
Dulbecco’s buffered saline (MP Biomedicals) 4 times, treated with DEAE-dextran 30 
mg/ml (GibcoBRL) for 30 minutes and washed 4 more times with Dulbecco’s buffered 
saline. After the CSF sample was added, the monolayers were centrifuged at 3600 rpm 
at 4 °C for 1 hour. 1 ml of medium was added to the vials (as before, but with added 
glucose 0.03M, amphotericin 2.5 pg/ml, vancomycin 10 pg/ml, gentamicin 10 pg/ml 
and cycloheximide 4 pg/ml). The vials were incubated at 35 °C for 7 days with 
additional centrifugation on days 4, 5 and 6. On day 7, one monolayer of each type was 
kept for examination. The other monolayer was passaged by manually scraping off the 
cells and resuspending them in their growth medium; the cell suspension was divided 
between 2 freshly prepared monolayers and set up as previously described. These 
monolayers were incubated for a further 7 days, with centrifugation on days 11,12 and 
13, and were examined on day 14. Monolayers were fixed with methanol and then 
stained using the IMAGEN chlamydial lipopolysaccharide direct immunofluorescent 
antibody test kit (DAKO Diagnostics). The stained coverslips were examined under an 
ultraviolet (UV) microscope by a single, blinded reader.
2.4.1.1 Isolate identification
The cell culture isolate was identified by specific polymerase chain reaction-enzyme 
linked oligonucleotide assay (PCR-ELONA), polymerase chain reaction-restriction
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fragment length polymorphism (PCR-RFLP) and DNA sequencing of the omp2 gene 
according to the method of Hartley et al (2001).
2.4.2 Chlamydophila pneumoniae polymerase chain reaction
CSF aliquots of approximately 400 pi were collected and Chlamydophila pneumoniae 
concentrated by the same method as used for culture. Pellets were frozen at -70 °C and 
extracted in batches of 10. DNA was prepared from the pellet by a method adapted from 
Sriram et al (1999). For each extraction run, stock lysis buffer was prepared as 
previously (Sriram et al, 1999) but with the addition of approximately 50 elementary 
bodies of Chlamydophila trachomatis (in 0.5 pi of stock suspension 105 EBs/pl 
(Hartley et al, 2001)) per patient or negative or positive control sample. Chlamydophila 
trachomatis internal control was omitted from one extraction run. Lysis buffer was 
added to individual samples, which were vortexed and incubated overnight at 37 °C. 
Samples were then boiled for 10 minutes and made up to 550 pi with lOmM EDTA pH 
7.5; DNA was then extracted by phenol/ chloroform/isoamyl alcohol using the method 
of Sriram et al (1999). This was modified by the addition of glycogen in the final DNA 
precipitation step. The final DNA pellet was dried at 55 °C for 30 minutes before 
suspension in 50 pi of DNAase free water (Baxter).
PCR detection followed the method of Hartley et al (2001). Briefly, a single round PCR 
was performed using primers for conserved regions of the outer membrane 2 protein 
gene present in Chlamydophila trachomatis and Chlamydophila pneumoniae 
amplifying a 557 base pair (bp) product from Chlamydophila trachomatis and 584 bp 
product from Chlamydophila pneumoniae).
All reactions were carried out in a Perkin Elmer type 480 thermal cycler, in 50 pi 
reaction volumes. Reactions contained 20 pi of sample, 200pM each dNTP
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(Amersham-Pharmacia), 5 pmol each primer (Chi and Ch2-bio) and 1.25 units Taq 
gold polymerase (Roche Biochemicals). Amplification conditions were: 95 °C for 10 
min, 1 cycle; 94 °C, 1 min., 55 °C 1 min., 72 °C, 1 min., 40 cycles; and a final extension 
step of 72 °C, 7 min., 1 cycle.
The species-specific products are individually detected by a sensitive and specific 
chemiluminescent ELONA (Hartley et al, 2001). The ELONA is performed in duplicate 
for each probe. Under ideal conditions the PCR-ELONA is able to detect a single copy 
gene input into the PCR (Hartley et al, 2001). Presence of approximately 50 genome 
copies of one species does not prevent detection of a low number of another 
(unpublished data, J. Hartley). When the internal control is detected, a negative PCR- 
ELONA for Chlamydophila pneumoniae equates to below 50 genomes/400pi of CSF 
trypsin-EDTA pellet (125 genomes/ml CSF). Failure to detect the Chlamydophila 
trachomatis internal control demonstrates reduced efficiency in the overall process of 
extraction, amplification or detection, in that specific sample. As long as routine 
external PCR and ELONA positive controls are valid, a negative Chlamydophila 
pneumoniae result may be given but the level of sensitivity is not known. However, this 
is the usual situation for most assays, as they have no internal control.
2.4.3 Chlamydophila pneumoniae serology
Serum IgM and IgG antibodies to the family Chlamydiaceae, were assayed using 
ELISA kits from MED AC Diagnostika (Hamburg, Germany). The assay was performed 
according to manufacturer’s instructions, and included positive, negative and blank 
controls.
Any serum samples that were IgM or IgG antibody positive were further tested using 
microimmunofluoresence (MIF). MIF, regarded as the gold standard, was devised in 
1970 as an assay for Chlamydophila trachomatis (Kuo et al, 1995; Wang and Grayston,
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1970) and has been modified to incorporate testing for Chlamydophila pneumoniae. It is 
a specific and sensitive assay for chlamydial infection. Serum samples are tested against 
pools of antigens associated with specific serotypes, including a pool that is specific for 
Chlamydophila pneumoniae. The antigens used are derived from the major outer 
membrane protein. MIF slides were made up in-house in advance by dotting antigen 
suspensions on to 12-well PTFE coated slides and allowing to air dry. For the assay, 
dilutions of the patients’ sera from 1:8 to 1:512 were made and 10 pi of each dilution 
placed on each well. The slide was incubated in a humid chamber for 1 hour at 35 °C. 
Excess serum was rinsed away with PBS and the slide was air-dried. 10 pi of 
fluorescent conjugate containing anti-human IgG, IgM or IgA (Sigma) was added to the 
relevant wells and incubated in a humid chamber for 1 hour at 35 °C. The slide was 
washed, air dried and examined under the UV microscope at high-power oil immersion. 
A positive result for IgG was taken as a titre of equal to or greater than 256, and for 
IgM/IgA was a titre equal to or greater than 64.
2.5 Calculation of peak areas
The immunoblot was scanned on a GS-690 scanning densitometer (BioRad) at a
resolution of 100 dpi and saved as a proprietary file, <fllename.IMG>, using Molecular
Analyst/PC software provided with the densitometer. This was then converted into a tag
image file format (TIFF) file using the same software. The saved image was opened in
Irfanview 32 Bit software version 3.51 (Vienna University of Technology, Austria)
where it was converted to Greyscale and saved as a non-compressed TIFF file. The
image was then opened in ImageJ version 1.31 (Rasband, 1997-2005), a Java-based
programme. The image is calibrated using a scan of a Kodak photographic step tablet
scanned with an Epson Expression 1680 professional scanner (step-tablet-epson-
8bit.tif), available via the National Institutes of Health (NIH) website
65
(http://rsb.info.nih.gov/ij/docs/examples/calibration) as a ZIP compressed TIFF file, 
using the Rodbard curve fitting procedure developed for use with ImageJ (Figure 2.1). 
Rodbard is a four parameter general curve fit function proposed by David Rodbard at 
NIH. A box was drawn on the first lane, using the box-drawing tool, and copied to all 
subsequent lanes. On the command, Plot Lanes, a series of densitograms was generated 
corresponding to the separate traces on the blot. Using the line-drawing tool the peak 
area(s) to be measured were marked and then using the tracing tool the pixel densities of 
the areas were calculated by the programme for both the peaks and the total area under 
the curve. Peak areas were then expressed as a percentage of the total area (in pixel 
density) under the curve.
3.57
y =  c*((a-x)/(x-d))A(1/b)
000
Figure 2.1 Calibration curve for ImageJ.
Calculated using Rodbard curve-fitting procedure on data from scanned Kodak step 
tablet.
2.6 Total Protein Assay (BioRad)
10 pi of standards (0, 0.125, 0.25, 0.5, 1.0 and 2 mg/ml), quality controls (low and high) 
and unknowns were pipetted, in duplicate, into a standard 96 well ELISA plate. 25 pi of 
reagent A (alkaline copper tartate) was then dispensed into each well followed by 200
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pi of reagent B (Folin reagent). The plate was incubated on the bench for at least fifteen 
minutes to allow the colour to develop before absorbances were read at 750 nm in a 
plate reader (Wallac). A standard curve was constructed and the concentrations of the 
unknowns calculated from the standard curve.
2.7 Samples
2.7.7 Multiple Sclerosis and Chlamydophila pneumoniae study
A total of 48 subjects were recruited for the study of which 46 were analysed in this 
study. Two control patients were excluded due to lack of sample material. Nineteen 
subjects, (mean age 39.3 +/- 12.7, 10/19 (52.6%) male), had a clinical diagnosis of MS. 
Twenty-seven patients, (mean age 49.2 +/- 15.5, 16/27 (59.3%) male), with other 
neurological disease made up the control group of inflammatory diseases such as 
encephalitis or neurosarcoidosis, and non-inflammatory diseases such as dementia or 
epilepsy. Demographic data for each group is given in Tables 2.1 and 2.2. All patients 
were undergoing routine lumbar punctures for diagnostic purposes. Ethical approval 
was obtained prior to the study. All samples were coded so that the laboratory work was 
carried out blinded.
All blood samples were centrifuged at 2800 rpm for twenty minutes and the serum 
aliquotted into two or three tubes containing approximately 800 to 1000 pi each and 
labelled with study number.
2 ml of plasma from CPT tubes was aliquotted into two tubes, labelled and frozen, the 
remainder being mixed with 1.5 ml of phosphate buffered saline, the cells being 
resuspended and transferred to a V-bottom tube (Sarstedt), labelled PBMC. The tubes 
were centrifuged at 10000 rpm for 2 minutes, the supernatant removed and all tubes 
frozen at -70 °C.
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Four 800 pi aliquots of CSF were taken; one was divided into two equal aliquots and 
frozen along with one of the 800 jul aliquots at -70 °C.
Table 2.1 Control patient demographics for C. pneumoniae in MS study.
Study Age Sex Diagnosis
number
2 42 M Optic neuropathy
4 71 F Corticobasal degeneration
5 50 F Headache
6 49 M Whipples disease
8 11 M CONT
10 72 M Thoracic disc T11/T12
11 35 F Functional disorder
14 41 F Stroke
16 21 M Guillaine-Barre Syndrome
17 69 F Axonal neuropathy
18 31 M Recurrent migraine
21 44 M Motor neurone disease
22 40 F Trigeminal neuropathy
23 32 F Facial nerve disorder
24 61 M Brain abscess
26 69 F Alcohol-related ataxia
27 55 M Primary lateral sclerosis
28 61 M Cerebral infarct
30 53 M Whipples disease
36 50 M Neurosyphilis
37 57 M Myelopathy
38 60 M Axonal/demyelinating
neuropathy
62 34 M Headache
64 49 F Glioma
65 47 F Benign intracranial 
hypertension
68 68 F Myelopathy
69 57 M Cerebellar ataxia
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Table 2.2 MS patient demographics for G pneumoniae in MS study.
Study
number
Age Sex Diagnosis
7 51 F Primary progressive MS
9 21 M MS
12 36 F Relapsing remitting MS
13 48 F Relapsing remitting MS
15 50 M MS
19 49 M Relapsing remitting MS
25 55 M Relapsing remitting MS
29 53 M Relapsing remitting MS
31 21 F Relapsing remitting MS
32 39 M Relapsing remitting MS
34 35 F Relapsing remitting MS
35 32 F Relapsing remitting MS
39 36 F MS
52 32 F MS
61 48 M MS
63 16 F Primary progressive MS
66 61 M MS
67 34 M Relapsing remitting MS
70 29 M Relapsing remitting MS
2.7.2 Multiple Sclerosis and Acinetobacter calcoaceticus study 
Serum and CSF samples. Matched serum and CSF samples were obtained from 
routine patient admissions at the National Hospital for Neurology and Neurosurgery 
(NHNN), London, United Kingdom. All samples were received in the Department of 
Neuroimmunology for IEF for OCBs of IgG.
Twelve patients with confirmed MS (5 male, 7 female; age 45 +/- 9.8, World Health 
Organisation (WHO) International Classification of Diseases (ICD)-IO code G.35) 
(Table 2.4), and eight other patients with neurological disease; (3 female, 5 male; age
54.3 +/-14.4) (Table 2.3), were selected for the study. Eleven of the MS patients were 
recently diagnosed and not on therapy, the twelfth was on (3-IFN, having been 
diagnosed five years previously. Nine of the MS patients had relapsing-remitting MS 
and three primary progressive MS. Ten controls and 10 MS patients were originally 
selected but two of the controls were subsequently re-diagnosed as MS. All MS patients
had normal total protein levels and white cell counts. Three control patients had slightly 
raised total protein but normal white cell counts. One control (optic neuritis) had a white 
cell count of 26 (total protein normal) and a mirror pattern on IEF.
Table 2.3 Control patient demographics for A. calcoaceticus in MS study.
Study
number
Age Sex Diagnosis
Cl 66 F Optic neuritis
C2 57 F Progressive ataxia
C3 23 F Optic neuritis
C4 67 M Chronic inflammatory demyelinating polyneuropathy
C5 55 M Unspecified brain neoplasm
C6 48 M Headache syndrome
C7 53 M Unspecified dementia
C8 65 M Frontotemporal dementia, arteritis
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Table 2.4 MS patient demographics for A. calcoaceticus in MS study.
Study
number
Age Sex Diagnosis
MSI 31 M Primary progressive multiple sclerosis
MS2 47 M Relapsing-remitting multiple sclerosis
MS3 57 F Primary progressive multiple sclerosis
MS4 46 M Primary progressive multiple sclerosis
MS5 35 F Relapsing-remitting multiple sclerosis
MS6 51 M Relapsing-remitting multiple sclerosis
MS7 56 F Relapsing-remitting multiple sclerosis
MS8 42 M Relapsing-remitting multiple sclerosis
MS9 61 F Relapsing-remitting multiple sclerosis
MS10 36 F Relapsing-remitting multiple sclerosis
MS11 43 F Relapsing-remitting multiple sclerosis
MS12 35 F Relapsing-remitting multiple sclerosis
2.8 Enyme-linked immunosorbent assay and precipitation methods
2.8,1 Turbidimetric assay for precipitation by sodium thiocyanate
Goat anti-human albumin (DiaSorin) was double diluted in 0.9% saline from 1/50 down 
to 1/3200. 50 pi of each dilution was pipetted into positions one to eleven across the 
first seven rows, A to G. The eighth row, H, had 50 pi of saline in positions one to 
eleven, to act as a control. Saline or NaSCN, 5M or 10M, was then added in varying 
amounts (see Table 2.5) and the plate read at 340 nm to measure any resulting turbidity, 
the saline acting as a control.
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Table 2.5 ELISA plate format for investigation of turbidimetric effect of NaSCN.
Serum Sal Thio Sal Thio Sal Thio Sal Thio Sal Thio
1/50 5 pi 5pl lOpl lOpl 25 pi 25 pi 50pl 50pl lOOpl lOOpl
1/100 5 pi 5 pi lOpl lOpl 25 pi 25 pi 50pl 50pl lOOpl lOOpl
1/200 5 pi 5 pi lOpl lOpl 25 pi 25 pi 50pl 50pl lOOpl lOOpl
1/400 5 pi 5 pi lOpl lOpl 25 pi 25 pi 50pl 50pl lOOpl lOOpl
1/800 5pl 5 pi lOpl lOpl 25 pi 25 pi 50pl 50pl lOOpl lOOpl
1/1600 5pl 5 pi lOpl lOpl 25 pi 25 pi 50pl 50pl lOOpl lOOpl
1/3200 5pl 5pl lOpl lOpl 25 pi 25 pi 50pl 50pl lOOpl lOOpl
Saline 5pl 5 pi lOpl lOpl 25pl 25 pi 50pl 50pl lOOpl lOOpl
Key: Sal, saline; Thio, sodium thiocyanate.
2.8.2 Enzyme-linked immunosorbent assay affinity distribution
Alternate rows (A, C, E and G) of a 96-well ELISA plate (Nunc) were incubated with 
100 pi of 0.01% w/v HSA (10 mg/1) in 0.05M carbonate buffer at room temperature 
overnight, covered with clingfilm™. The wells were then washed out twice with 200 pi 
0.9% saline before being incubated with 100 pi of 5M NaSCN for 15 minutes. The 
wells were then washed twice more with 0.9% saline before being blocked with 1% 
gelatin in 0.9% saline for 30 minutes on a shaking platform. 100 pi of goat anti-HSA 
diluted 1/250000 in 0.9% saline was then dispensed into each well and the plate 
incubated at room temperature on a platform shaker for one hour after which the plate 
was decanted. Saline and 10M NaSCN respectively, were then added in varying 
amounts to a final volume of 200 pi of 0M, 1.25M, 2.5M, 5M and 10M NaSCN in 
columns 1 and 2, 3 and 4, 5 and 6, 7 and 8 and 9 and 10, respectively, (see Table 2.6). 
This enabled us to repeat all estimations in duplicate and the experiment in 
quadruplicate.
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The plate was incubated with NaSCN for 30 minutes after which the NaSCN was 
decanted and the plate rinsed out with gently flowing tap water for approximately 30 
seconds. The wells were then incubated with 100 pi of RAG serum conjugated to HRP, 
diluted 1/1000 in 0.9% saline/0.2% skimmed milk, on a platform shaker at room
Table 2.6 Addition of saline and NaSCN in the affinity distribution ELISA.
Columns Saline 
added (pi)
10M NaSCN added
m
Final molarity 
NaSCN
1 and 2 200 0 0
3 and 4 175 25 1.25
5 and 6 150 50 2.5
7 and 8 100 100 5
9 and 10 0 200 10
temperature for one hour. The wells were then washed four times with 200 pi of 0.1% 
gelatin/0.025% Tween 20/0.9% saline. 50 pi of o-phenylenediamine (OPD) solution 
was added to each well and the plate kept in the dark whilst the colour developed, apart 
from periodic checks to monitor colour development. When there was sufficient colour 
the colour reaction was stopped with 50 pi 1M HC1 and the plate read at 490 nm, 
blanked at 405 nm, on a Victor2 1420 multilabel counter (Wallac). Affinity distribution 
was calculated by first subtracting the blank absorbance from every reading, then 
subtracting the net absorbances of the control (non-HSA-coated) wells from the net 
absorbances of the test (HSA-coated) wells before averaging the final duplicate 
absorbances at each different molarity of NaSCN. The absorbance at 0M NaSCN 
(saline) was taken as representing total specific IgG. The differences between the final
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absorbances at each molarity of NaSCN were expressed as a percentage of total specific 
IgG using the following formulae according to the method of Luxton and Thompson 
(1990).
((ODgaiine -  ODj 25M NaSCN)/ODsaline) X 100 
((ODi 25M NaSCN ~ OD2.5MNaSCN)/ODsaline) X 100 
((OD2.5M NaSCN ~ OD5M NaSCN)/ODSaline) X 100 
((OD5M NaSCN ~ ODiOMNaSCNyODsaline) X 100 
where OD = optical density i.e. absorbance
2.9 Rocket electrophoresis to quantitate serum and cerebrospinal fluid IgG
An agarose gel, 6 mm thick, (see Section 3.6) was prepared in advance and stored at 4 
°C wrapped in clingfilm™ until use. The gel was placed on the cooling platten of an 
electrophoresis tank (Amersham) containing barbitone buffer and the wicks positioned 
to overlay the edge by approximately one centimetre. 4 pi of standards (50, 40, 30,20, 
10 and 5 mg/1), serum samples, (diluted 1 in 201), and CSF samples, (run neat and at 1 
in 5 dilution) were pipetted, in duplicate, into two rows of wells cut into the gel. The gel 
was then run overnight at 150 V and an approximate current of 25 mA. The gel was 
removed from the tank and pressed under six sheets of filter paper, a glass plate and a 1 
kg weight for ten minutes. The gel was then submerged in 0.9% saline for 30 minutes 
before being pressed as before and then dried using a hairdrier. Next, the gel was 
submerged in stain, (Coomassie Brilliant Blue), for 30 minutes, after which it was 
rinsed in tap water, blotted as before and dried. Finally, the gel was placed in destain 
until the background was clear, washed in tap water, blotted and dried. Peak heights 
were measured and a standard curve constructed from which the concentration values of 
the unknowns were determined.
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2.10 Statistical analyses
2.10.1 General Linear Model
The general linear model (GLM) is used to compare values from more than two groups 
of non-normally distributed data. Initial analysis gives an F value, which is used to 
determine overall significance. If p<0.05 then post hoc analysis by least squares means 
regression analysis is performed.
2.10.2 Mantel-Haenszel Chi Square
The Mantel-Haenszel chi-square is used to establish whether there is a linear association 
between more than two sets of variables. Significance in this test shows that increases in 
one variable are associated with increases in the other greater than would be expected 
by chance alone.
2.10.3 Fisher Exact Probability Test
The Fisher exact probability test is a non-parametric technique for analysing two small 
samples, the results of each observation being one of only two possible outcomes.
Scores are given as frequencies and the test determines whether the two groups differ in 
the proportion of the frequencies of the two outcomes.
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3.0 Materials
3.1 Buffers
3.1.1 Acetate buffer
Stock acetate buffer (0.2M): Dissolve 136 g of sodium acetate trihydrate (Sigma) and
22.5 ml of glacial acetic acid (BDH) in deionised water and adjust pH to 5.1, if 
necessary. Make up to 5 litres with deionised water.
Working acetate buffer (0.02M): Dilute stock acetate buffer 1 in 10 with deionised 
water.
3.1.2 Carbonate buffer
Stock carbonate buffer (0.5M): Dissolve 6.93 g of sodium carbonate (Sigma) and
13.05 g of sodium hydrogen carbonate (Sigma) in 500 ml of deionised water to make a 
0.5M solution.
Working carbonate buffer (0.05M): Dilute stock carbonate buffer 1 in 10 with 
deionised water.
3.1.3 Barbitone buffer for rocket electrophoresis
10.5 g diethylbarbituric acid Sigma), 65.0 g sodium barbitone (Sigma) and 2.0 g 
calcium lactate (Sigma) are dissolved in 2 1 of distilled water. The solution is made up 
to 5 1 with distilled water and 5 ml thymol (Sigma) solution added.
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3.2 Sodium thiocyanate
Stock sodium thiocyanate solution (10M): Dissolve 202.68 g of NaSCN (Sigma) in 
250 ml deionised water.
Working solutions (1.25M, 2.5M, 5M): 1.25M, add 3.125 ml of stock solution to 
21.875 ml deionised water; 2.5M, add 6.25 ml stock solution to 18.75 ml deionised 
water; 5M, add 12.5 ml stock solution to 12.5 ml deionised water.
3.3 Saline solutions
0.9% Saline: Dissolve 90 g of sodium chloride (Sigma) in 10 litres of deionised water. 
0.9% Saline/lmM EDTA: Dissolve 2 g of EDTA in 5 litres of 0.9% saline.
3.4 Electrode solutions for isoelectric focusing
Sodium hydroxide (1M) (catholyte): Dissolve 40 g sodium hydroxide (Sigma) in 
deionised water and make up to 1 litre.
Sulphuric acid (0.05M) (anolyte): Add 1.35 ml concentrated sulphuric acid (BDH) to 
500 ml deionised water.
3.5 Colour reagents
3,5.13-amino-9-ethyl carbazole
Dissolve 50 mg of 3-amino-9-ethyl carbazole (Sigma) in 20 ml ethanol (Hayman) and 
add 100 ml working-strength acetate buffer (see section 3.1.1). Add 100 pi 30% v/v 
hydrogen peroxide just before use.
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5.5.2 4-chloro-l-naphthol
Dissolve 0.25 mg of 4-chloro-l-naphthol in 10 ml ethanol; add 50 ml of 0.02M acetate 
buffer. Add 50 pi 30% v/v hydrogen peroxide (Sigma) just before use.
5.5.5 O-phenylenediamine
Dissolve 10 mg OPD (Sigma) in 10 ml 0.02M acetate buffer and add 12 pi of 30% v/v 
hydrogen peroxide just before use.
3.5.4 Coomassie Brilliant Blue and destain
Dissolve 2 g Coomassie Brilliant Blue (Sigma) in 350 ml ethanol. When the stain has 
dissolved add 550 ml distilled water and 100 ml glacial acetic acid (BDH). Destain 
solution is 550 ml distilled water, 350 ml ethanol and 100 ml glacial acetic acid.
3.6 Agarose gel for rocket electrophoresis
In a glass, screwtop bottle dissolve 6 g PEG 6000 (BDH) in 200 ml of barbitone buffer 
(see Section 3.1.3) and add 2 g high electroendosmosis agarose (HEEO) (BMA 
Products) and 1 g medium electroendosmosis agarose (MEEO) (BMA Products). Place 
in a boiling water bath until the gel has fully dissolved, then aliquot 25 ml volumes into 
glass, screwtop bottles and store at 4 °C. To make a gel for IgG rocket electrophoresis 
take one of the 25 ml aliquots and place into a boiling water bath until dissolved. Then 
transfer the bottle to a water bath at 65 °C for 30 minutes to allow the gel to cool to 65 
°C. Cut a sheet of GelBond to 23 cm x 12 cm and seal on the surface of a glass plate 
using 50:50 water: methanol. On top place a second glass plate with attached spacer of 
6 mm depth and clamp the apparatus together. Warm gently under a hairdrier. Add 80 
pi of goat anti-human IgG Fc (Dako, ) and mix gently to avoid frothing. Using a warm
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syringe and needle transfer gel into casting frame. When set, the gel is wrapped in 
clingfilm™ and stored for up to one week at 4 °C.
3.7 Antibodies and their dilutions 
Model method antibodies:
First antibody -  rabbit anti-goat (RAG) polyclonal (Dako) diluted 1 in 2500 i.e. 10 pi of 
antibody in 25 ml of 0.2% w/v skimmed milk in 0.9% saline.
Second antibody -  swine anti-rabbit polyclonal conjugated with horseradish peroxidase 
(SAR-HRP) (Dako) diluted 1 in 5000 i.e. 5 pi of antiserum in 25 ml of 0.2% w/v 
skimmed milk in 0.9% saline.
Band comparison in SSPE study and affinity maturation study in HSE antibodies:
First antibody -  goat anti-human IgG (Diasorin) diluted 1 in 2500 i.e. 10 pi of antibody 
in 25 ml of 0.2% w/v skimmed milk in 0.9% saline.
Second antibody - RAG conjugated with HRP (RAG-HRP) (Dako) diluted 1 in 5000 i.e. 
5 pi of antibody in 25 ml of 0.2% w/v skimmed milk in 0.9% saline.
Acinetobacter calcoaceticus in MS study antibodies:
First antibody -  goat anti-human IgG (Diasorin) diluted 1 in 2500 i.e. 10 pi of antibody 
in 25 ml of 0.2% w/v skimmed milk in 0.9% saline/1 mM EDTA/0.1% v/v Tween 20. 
Second antibody -  RAG conjugated with HRP (Dako) diluted 1 in 5000 i.e. 5 pi of 
antibody in 25 ml of 0.2% w/v skimmed milk in 0.9% saline/lmM EDTA/0.1% v/v 
Tween 20.
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Chlamydophila pneumoniae in MS study antibodies for Western blotting:
Rabbit anti-human IgG, IgM, IgA, k  light chain and X light chain conjugated to HRP 
(Dako) diluted 1/1000 i.e. 25 pi antibody in 25 ml 0.9% saline/0.2% w/v skimmed milk 
for each manifold.
ELISA for affinity distribution:
First antibody -  goat anti-human albumin (Diasorin) diluted 1/250000 i.e. stock solution 
of 10 pi in 250 ml 0.9% saline further diluted 1/10 i.e. 10 ml stock made up to 100 ml 
with 0.9% saline.
Second antibody - RAG polyclonal conjugated to HRP, diluted 1/1000 i.e. 25 pi 
antibody in 25 ml 0.9% saline/0.2% skimmed milk.
3.8 Software applications used
3.8.1 Irfanview
Irfanview is a freeware graphics viewer for Windows developed by Irfan Skiljan at the 
University of Vienna. Version 3.51 was used.
3.8.2 ImageJ
ImageJ is a freeware Java-based program for image processing and analysis developed 
at the NIH, USA.
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4.0 Results
4.1 Model method
4.1.1 Model method results
The aim of the model method was to show, using commercial antigen and antisera, that 
the method could be used to investigate the relative affinity o f  individual clones. The 
final blots had to be o f sufficient quality for them to be scanned and subjected to the 
software analysis.
On each blot, six replicates o f commercial goat anti-HSA, diluted 1/1000 in 0.9% 
saline, and isoelectrically focused, were incubated with each o f the four different 
molarities o f NaSCN. After development, blots were dried and scanned ready for peak 
analysis. An example is given (Figure 4.1).
For all subsequent images o f blots the cathodal edge is at the top o f the image.
For all images o f densitograms the cathodal end is at the left o f the image.
f f f V I f f  9 f v | « i  • «p v i l l
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□Ml 1.25M 2.5M 5M
Figure 4.1 Complete trace of model method blot 3.
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One representative band was identified as being o f sufficient strength to be the “target” 
band (Figure 4.2). The pixel density o f this band was then calculated for each trace in 
each assay and used to generate the statistics (Figure 4.3).
•  9«'  m
A B C D
Figure 4.2 Examples of IEF trace from model method blot 18.
Key: A, OM; B, 1.25M; C, 2.5M; D, 5M NaSCN. Representative high affinity band is 
indicated with arrow.
Some traces were not suitable for peak analysis due to problems that occurred during 
the running o f the gel; principally, skewed traces that could not be accommodated by 
the software and traces with discrete areas o f inappropriate colour development, both 
too heavy and too light. All observations were made on at least three measurements, as 
indicated in Table 4.1.
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Figure 4.3 Densitograms of IEF traces from Figure 4.2.
Key: A, 0M; B, 1.25M; C, 2.5M; D, 5M NaSCN. Peak outlined is the peak calculated as 
a percentage of total area. Plots are not shown at relative scale.
Twenty blots were run, of which two were unsuitable for any analysis due to skewed 
traces. Of the remaining eighteen, five were rejected on the basis that there were not 
three or more measurable replicates at each molarity. The results of these thirteen 
complete blots (Table 4.1, Figures 4.4 and 4.5) were used to test for further statistical 
analysis.
Little difference can be seen between the overall values from 0M, 1.25M and 2.5M 
NaSCN although there is an upward trend, which is reflected, in most of the individual 
sets of values, i.e. 10/13 values at 5M are above the highest value of the 0M group.
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Table 4.1 Peak area of target band (pixel density)
Molarity of sodium thiocyanate
0M 1.25M 2.5M 5M
ID Area± CV Area ± SD CV Area± CV Area ± SD CV
SD % % SD % %
All 2.8 ± 1.3
(n)
46.1 3.7 ±2.0
(n)
52.6 4.6 ± 2.4
(n)
52.2 9.8 ±5.4
(n)
55.2
1 4.8 ±0.5
(13)
10.9 6.0 ± 0.7
(13)
11.7 6.5 ± 0.8
(13)
12.3 15.8 ±2.3
(13)
14.9
2 5.4 ± 0.4
(6)
7.5 8.9 ±2.5
(6)
27.9 10.8 ±2.5
(6)
23.0 15.7 ±4.0
(6)
25.4
3 2.9 ± 0.3
(3)
11.6 3.8 ±0.5
(5)
14.2 4.7 ± 0.5
(5)
10.2 14.8 ±2.8
(6)
18.8
6 3.3 ± 0.9
(4)
27.3 3.7 ±0.8
(6)
22.2 5.5 ± 0.9
(6)
16.5 8.2 ± 0.5
(6)
5.6
9 3.4 ± 0.2
(6)
4.9 3.5 ± 0.2
(6)
6.0 4.1 ±0.3
(6)
7.9 9.3 ± 1.7
(6)
18.6
10 2.5 ±0.1
(6)
4.9 3.2 ±0.3
(5)
8.6 4.4 ± 0.2
(4)
5.0 7.0 ±1.4
(6)
20.2
12 1.7 ±0.1
(3)
3.4 2.7 ±0.2
(4)
6.9 3.1 ±0.2
(5)
7.7 5.6 ±0.9
(6)
8.8
13 1.3 ±0.2
(6)
15.2 2.2 ± 0.5
(5)
23.0 1.8 ±0.3
(3)
14.1 3.1 ±0.3
(6)
9.1
14 2.1 ±0.3
(6)
12.0 2.5 ± 0.4
(3)
18.0 2.5 ± 0.2
(6)
8.5 5.9 ±0.5
(6)
8.8
15 1.4 ±0.1
(6)
3.6 2.5 ± 0.4
(6)
15.2 2.4 ± 0.5
(6)
21.4 4.5 ± 0.6
(6)
13.1
16 1.1 ±0.2
(3)
20.4 1.7 ±0.2
(6)
8.6 1.5 ±0.3
(6)
19.6 3.4 ±0.7
(6)
19.0
17 3.1 ±0.4
(6)
14.2 4.4 ± 0.7
(3)
16.4 6.5 ± 1.1
(5)
16.4 10.0 ± 1.1
(6)
14.9
18 2.2 ± 0.3
(6)
14.0
(6)
3.0 ±0.3
(3)
10.6
(6)
4.3 ± 1.3
(4)
30.8
(4)
18.5 ±6.7
(6)
36.5
(6)
Areas expressed as a percentage of total area under curve.
Values given ± standard deviation with number of observations, (n), in brackets.
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4.1.1.1 Statistical analysis
There was a significant difference in the pixel density of the chosen peak F (3,48) =
11.81, p < 0.0001. The subsequent post hoc analysis by multiple squares regression 
analysis revealed that this was due to a significant higher relative pixel density at the 
5M concentration compared to the 0M, 1.25M and 2.5M concentrations of NaSCN. No 
direct quantitative statistical difference could be demonstrated between the 0M, 1.25M 
and 2.5M concentrations (Table 4.2).
Table 4.2 Results of post hoc statistical analysis by multiple squares regression 
analysis of comparisons of pixel density between NaSCN incubations in model
method.
Molarity of NaSCN 0M 1.25M 2.5M 5M
0M NS NS p<0.0001
1.25M NS NS p<0.0001
2.5M NS NS P=0.0002
5M p<0.0001 p<0.0001 p=0.0002
Key: Significant values are shown in bold italic; non-significant values are indicated by 
NS (Not Significant).
However, on a categorical level, comparing proportions of samples above and below 
cut-off, the trend analysis also demonstrated a significant increase (x2 = 18.13, p < 
0.001) in relative pixel density with increasing concentrations of NaSCN. The cut-off 
value was defined as the highest value within the 0M set of observations, which was 
5.4%, therefore the 0M group contained 0/13 values above cut-off i.e. 0%. In the 1.25M 
group 2 of 13 values were above the cut-off, equating to 15%. This figure then doubled 
to 4/13 in the 2.5M group, 31%, and was further increased to 10/13 in the 5M group 
(77%).
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In order to show that it is antigen-specific high affinity antibody pixel densities were 
compared, derived from the densitogram, o f the target band with underlying polyclonal 
background (band/polyclonal) with an area of polyclonal IgG (see Figure 4.6) for blots 
3 and 18. Both measured areas were 25 pixels wide and the two were separated by 60 
pixels. Measurements were always begun from the bottom left o f the target peak. At 
each molarity six measurements were taken and averaged for band/polyclonal and 
polyclonal areas; the ratio being generated by dividing the band/polyclonal area pixel 
density by the polyclonal area pixel density (Table 4.3).
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Figure 4.4 Line plots of all blot values for model method.
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Figure 4.5 Average values of all blots for model method.
Error bars are 1 SD above and below.
Band/poly
Poly
A B C D
Figure 4.6 Areas used for band/polyclonal and polyclonal ratio in model method.
Key: A, OM; B, 1.25M; C, 2.5M; D, 5M NaSCN.
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Table 4.3 Ratio of band/polyclonal to polyclonal pixel density.
NaSCN (M) 0 1.25 2.5 5
Blot 3 2.29 2.56 2.45 12.80
Blot 18 2.36 2.07 2.34 16.03
This shows that while there is little difference at 0, 1.25 and 2.5M NaSCN, at 5M 
NaSCN the ratio rises markedly, confirming that the polyclonal background is 
diminished in proportion to the bands of antigen-specific IgG, which are of higher 
affinity.
4.1.2 Blocking the membrane
Ultrabind (UB450) membrane is a covalent binding membrane containing active 
aldehyde groups that bind free amino groups, thus binding proteins to the membrane. 
Solutions containing primary amines could therefore be used to block any available 
binding sites once the antigen of interest has been bound to the membrane. The 
manufacturer’s recommendations for blocking the membrane included 1% skimmed 
milk in saline, which was initially adopted, although subsequently 2% skimmed milk in 
saline was used according to normal practice in the laboratory.
Experiments with anti-human albumin serum blotted onto a membrane coated only with 
milk proteins showed faint patterns indicating that the blocking may not have been 
complete. A similar experiment blocking the membrane with 1% Tris in saline also 
failed to block the membrane completely (Figure 4.7). A combination of 1% Tris and 
2% skimmed milk in saline was successful in completely blocking the membrane and 
was subsequently adopted for all work with Ultrabind membrane (Figure 4.8). Anti­
human albumin serum was double diluted from 1/500 to 1/16000 for these experiments.
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Figure 4.7 Goat anti-HSA blotted against Tris-coated membrane and incubated
with sodium thiocyanate.
i ft
OM 1.25M 2.5M 5M
Figure 4.8 Goat anti-HSA blotted against milk/Tris-coated membrane and
incubated with sodium thiocyanate.
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4.1.3 Enzyme-linked immunosorbent assay affinity distribution for anti-HSA
The aim of this ELISA was to show, independently o f affinity immunoblotting, that 
goat anti-HSA serum did contain antibodies of sufficient affinity for HSA to resist 
elution by 5M NaSCN.
The relative affinities were 100.0% at 0M NaSCN (saline), 41.9% at 1.25M NaSCN, 
38.1% at 2.5M NaSCN, 10.5% at 5M NaSCN and 7.6% at 10M NaSCN.
The results show that there is high affinity antibody present in the commercial goat anti- 
HSA serum. 18.1% o f the total anti-albumin IgG in the sample is o f sufficiently high 
affinity to resist at least 5M NaSCN (Figure 4.9).
Affinity distribution of anti-HSA
c
£CO
<D>+5
J2<D
a:
120
100
80
60
40
20
0
1.250 2.5 5 10
NaSCN (M)
Figure 4.9 Affinity distribution histogram for anti-HSA serum.
4.2 Comparison of band in serum and cerebrospinal fluid in subacute sclerosing 
panencephalitis
A paired serum and CSF sample was taken from a patient routinely admitted to NHNN, 
known to be suffering from SSPE. This was a confirmed diagnosis, with a specific 
measles IgG index o f 71.13, assayed at Colindale Public Health Laboratory. Serum anti­
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measles IgG was measured at 13164 mlU/ml, serum albumin 40 g/1, whilst CSF anti­
measles IgG was 1264 mlU/ml, with CSF albumin of 54 mg/1. The index was thus 
calculated as:
(CSF IgG/serum IgG) x (serum albumin/CSF albumin)
i.e.
(1264/13164) x (40000/54) = 71.13 
Routine IEF in this laboratory showed the patient to have a “greater than” pattern 
(Anderssen et al, 1994) with the CSF pattern showing many more bands, and which 
were considerably stronger. Routine antigen immunoblotting revealed a similar pattern 
(see Figure 4.10).
M easles Control 
Total IgG antigen antigen
S C  S C  s c
Figure 4.10 Routine blots of SSPE patient.
Key: S, serum; C, CSF.
Measurements o f total IgG in serum (9.35 g/1) and CSF (88 mg/1), by rocket 
electrophoresis, gave a ratio o f 1:106.25 which was used as the dilution factor in the
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experiment. Three replicates of serum and three of CSF of the SSPE sample at each of 
the four molarities of thiocyanate (OM, 1.25M, 2.5M and 5M) were run (see Table 4.4).
Table 4.4 Dilutions and final IgG concentrations for SSPE sample.
NaSCN
molarity
Serum
dilution
Total IgG 
(mg/1)
CSF dilution Total IgG 
(mg/1)
0 2124 4.4 20 4.4
1.25 1062 8.8 10 8.8
2.5 1062 8.8 10 8.8
5 106.3 88 Neat 88
The experiment was controlled with three clinically diagnosed paired MS samples, 
diluted to the same concentrations of IgG as in the SSPE sample, blotted against a 
measles-coated membrane (see Figure 4.12). The first control sample was from a patient 
with primary progressive MS, a “greater than” pattern on routine IEF serum IgG of 5.9 
g/1 and CSF IgG of 87 mg/1. The second and third were both patients with relapsing- 
remitting MS with routine IEF patterns showing bands in CSF, but not in serum. The 
second patient had serum IgG of 15.5 g/1 and CSF IgG of 44 mg/1 and the last control 
patient had serum IgG of 5.9 g/1 and CSF IgG of 45 mg/1. The last two control CSF 
samples were applied at 8 pi, the first application of 4 pi being allowed to soak in 
before the second application of 4 pi. Finally, all four samples were appropriately 
diluted and blotted against a membrane coated only with control antigen, the control 
antigen being a freeze-dried preparation of the cell line that the virus is grown in (see 
Figure 4.11).
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Figure 4.11 Three MS controls and SSPE sample against measles control antigen.
Key: SP, SSPE sample; M, MS sample; S, serum; C, CSF.
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Figure 4.12 Three MS controls against measles antigen.
Key: MS, MS patient; S, serum; C, CSF.
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A representative SSPE peak was identified (see Figure 4.13; arrowed, peak A) and its 
pixel density determined as a percentage o f the pixel density o f an area o f the trace 
around it (see Figure 4.13; box). It was not measured as a percentage o f the whole trace 
due to areas o f saturation that were unavoidable even as a result o f the dilutions. The 
trace at 5M NaSCN (see Figure 4.13) has become blurred and unreadable due to the 
presumed effect o f high-strength thiocyanate.
I #
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OM 1.25M 2.5M 5M
Figure 4.13 Paired sample of SSPE patient after exposure to NaSCN.
Key: S, serum; C, CSF.
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Figure 4.14 Densitograms of SSPE samples.
Not shown to relative scale.
From the densitograms it can be seen that IgG is lost from the cathodal end (left) of the 
trace in both serum and CSF, as indicated in the area marked with X (see Figure 4.14). 
In serum, it is lost mainly with incubation ini .25M NaSCN whereas in the CSF some is 
lost at 1.25M but most is stripped at 2.5M NaSCN. Visual examination of the peaks A, 
B and C show that in serum the peak heights remain in approximately the same ratio 
throughout, but in CSF peak A is taller than its neighbours, which retain their ratio. This 
suggests that CSF contains more high affinity IgG than serum and that peak A 
corresponds to a band of higher concentration in CSF than serum. Unfortunately, the the 
traces at 5M NaSCN could not be studied due to interference.
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Table 4.5 Areas of band A used in comparison study on SSPE patient.
Pixel density of target band (% of Mean + SD 
selected area, see Figure 4.13)
0M NaSCN Serum 5.0 6.6 5.3 5.6 + 0.85
CSF 10.3 11.0 9.3 10.2 + 0.85
1.25M Serum 7.1 6.9 6.8 6.9 + 0.15
NaSCN CSF 11.6 11.3 9.3 10.7+1.25
2.5M Serum 6.9 14.1 13.9 11.6 + 4.10
NaSCN CSF 21.0 26.2 29.5 25.6 + 4.29
The data show that the serum band, on average is 2.1 times higher at 2.5M NaSCN than 
at OM, whilst the CSF band, on average, is 2.5 times higher over the same interval 
(Table 4.5, Figure 4.15).
Comparisons could not be made across the range of molarities as samples were diluted 
differently at 1.25 and 2.5M as opposed to OM (see Table 4.4). No results could be 
obtained from the 5M NaSCN traces due to repeatedly poor quality of the traces 
because of the interference effects of high molarity thiocyanate (Gray and Shaw, 1992; 
McMahon and Kennedy, 2000; Bouvet et al, 2001a; Bouvet et al, 2001b).
In order to see whether there were any significant differences between the three 
replicate serum and three replicate CSF results at each molarity categorical data analysis 
was used. To enable a categorical data analysis the highest pixel density observed for 
serum samples was defined as cut-off (pixel density = 6.6 for 0M, pixel density = 7.1 
for 1.25M, pixel density = 14.1, 2.5M).
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Figure 4.15 Pixel density of target band in SSPE patient serum and CSF.
Error bars are 1 SD
A significantly higher proportion of CSF samples (100%, 3/3) had pixel density levels 
above cut-off compared to the serum samples (0%, 0/3) for each o f the comparisons 
(p<0.05, Fisher’s exact test).
The area o f the target band plus the polyclonal background beneath it,
(band/polyclonal), was compared with an area o f polyclonal background, both o f width 
20 pixels, across all the molarities, to calculate the ratio o f band/polyclonal to 
polyclonal (see Table 4.6, boxed areas in Figure 4.16) in CSF. This could not be done in 
the serum as there was no signal in the corresponding polyclonal area. The ratio was 
calculated by dividing the band/polyclonal pixel density by the polyclonal pixel density.
Table 4.6 Band/polyclonal to polyclonal ratios for target band in SSPE CSF.
NaSCN (M) 0 1.25 2.5
Ratio 0.91 1.30 1316
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The ratio shows little change between OM and 1.25M NaSCN but climbs to 1316 at 
2.5M due to the absence o f any signal in the polyclonal area. A nominal value of 1 was 
therefore applied to prevent division by zero.
Polyclonal
P eak  A
OM 1.25M 2.5M
Figure 4.16 Band/polyclonal and polyclonal areas for ratio calculation in SSPE.
4.3 Affinity maturation in Herpes simplex encephalitis
A series o f three paired serum and CSF samples was obtained from a 68 year old female
admitted to the NHNN suffering from suspected encephalitis. The first paired sample
was taken the day after admission and showed 200 lymphocytes/mm3 in the CSF, a
mirror pattern on routine IEF, albeit with subtle bands, stronger in CSF than serum, and
positive for Herpes simplex type 1 by PCR for DNA. The mirror pattern was confirmed
by staining separately for k  and X light chains as the CSF trace was stronger, due to the
raised total IgG. The patient was started on acyclovir therapy on admission. The second
paired sample was from 6 days after admission and had the same IEF result for OCBs
and a reported white cell count o f 190 white cells/mm3, which were predominantly
lymphocytes. PCR for DNA was now negative. The final sample, 15 days after
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admission, was again negative for viral DNA by PCR and the white cell count had 
dropped to 36 white cells/ mm3. IEF for OCBs now showed a pattern of more bands in 
the CSF than in the serum (Table 4.7).
Total IgG was calculated for all samples by rocket electrophoresis. This enabled all 
samples to be diluted to 26, 52 and 104 mg/1 total IgG for three complete affinity blots.
Table 4.7 Results summary for serial samples on patient with HSE.
First sample Second sample Third sample
Day after 1 6 15
admission
Serum IgG (mg/1) 7585 15170 16367
NR 5000 to 10000
CSF IgG (mg/1) 260 845 696
NR 5 to 25
PCR for HSV1 Positive Negative Negative
DNA
White cell count 200 lymphocytes 190, predominantly 36, predominantly
(mm3) NR <5 lymphocytes lymphocytes
Total protein (g/1) 1.90 3.10 2.27
NR 0.10 to 0.60
Key: NR, normal range.
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Figure 4.17 Original traces for HSE patient.
Key: S, serum; C, CSF.
At all three dilutions the day 1 paired sample had only a few faint bands compared with 
the days 6 and 15 paired samples although more bands could be seen at 104 mg/1 IgG 
than at 26 mg/1 IgG. There was also a notable increase in the polyclonal background as 
the sample dilutions decreased. At all dilutions the bands in the day 1 sample were lost 
at 5M NaSCN whilst they were plainly visible for the days 6 and 15 paired samples. At 
52 mg/1 total IgG the bands could not be reliably distinguished at 5M NaSCN due to 
presumed high molarity thiocyanate interference. Interestingly, this was the latest of the 
experiments on this series, the blot at 104 mg/1 being run first, the blot using 26 mg/1 
run five days later and the blot using 52 mg/1 six days after that. All o f the paired 
samples were controlled by blotting against herpes control antigen (see Figure 4.17). It 
was decided to use the blot o f 23 mg/1 for the subsequent work (Figure 4.18).
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Figure 4.18 Blot of HSE series at 26 mg/1.
Key: Arrows indicate three bands quantified, identified as A (top), B (middle) and C 
(bottom). S, serum; C, CSF.
Table 4.8 Pixel density of total area under the curve for HSE series.
NaSCN (M) OM 1.25M 2.5M 5M
Day 1 Serum 5705 0 172 2781
Day 1 CSF 8312 100 1030 844
Day 6 Serum 12356 6385 6509 2954
Day 6 CSF 27394 29779 25056 11846
Day 15 Serum 17139 15506 10482 6368
Day 15 CSF 51306 46828 36807 13839
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Table 4.9 Pixel densities for the target bands at day 6 of HSE series.
NaSCN (M) Sample Band A (%) Band B (%) Band C (%)
0 Serum 3.6 1.5 2.8
CSF 0.8 1.0 1.7
1.25 Serum 11.4 6.8 9.2
CSF 1.0 1.1 1.7
2.5 Serum 14.2 9.5 9.9
CSF 2.5 1.7 1.9
5 Serum 18.6 16.2 15.3
CSF 5.2 4.0 5.7
Areas expressed as percentage of total area under the curve. 
Key: S, serum; C, CSF.
Three bands, as indicated in Figure 4.18, were quantified using ImageJ on a digitised 
blot for day 6 and day 15 samples (Tables 4.9 and 4.10, Figures 4.20 and 4.21). No data 
could be extracted from the digitised blot for the first sample.
Table 4.10 Pixel densities for the target bands at day 15 of HSE series
NaSCN (M) Sample Band A (%) Band B (%) Band C (%)
0 Serum 3.1 1.9 1.7
CSF 0.8 0.6 0.5
1.25 Serum 4.0 2.9 2.7
CSF 0.8 0.9 0.8
2.5 Serum 6.6 3.9 4.2
CSF 1.4 1.1 1.0
5 Serum 16.0 9.7 9.6
CSF 4.1 3.7 3.1
Areas expressed as percentage of total area under the curve.
Key: S, serum; C, CSF.
The total pixel density for each trace at 26 mg/1 (Figure 4.18) was plotted against time 
(Figure 4.19) to show the increase in total specific IgG.
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Figure 4.19 Plot of total pixel density against time for HSE.
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Figure 4.20 Target bands on day 6 in HSE patient.
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Figure 4.21 Target bands on day 15 in HSE patient.
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Figure 4.22 Densitograms of day 6  sample in HSE patient.
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Figure 4.23 Densitograms of day 15 sample in HSE patient.
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Looking at the area marked X (see Figures 4.22 and 4.23), anodal to peak C, on the 
densitograms it was seen that at day 6, the IgG here is largely lost in the serum at 1.25M 
NaSCN and completely at 2.5M NaSCN, suggesting this IgG to be o f low affinity. In 
the CSF, the same area shows little difference at 1.25M, is reduced at 2.5M NaSCN but 
is not lost until 5M NaSCN is applied. The findings are the same for CSF on day 15, but 
in serum there is still IgG present at 1.25m NaSCN. Only at 2.5M NaSCN is the IgG 
virtually absent from the area. This shows that whilst the IgG in the CSF is o f higher 
affinity than in the serum at days 6 and 15, the serum IgG is o f higher affinity at day 15 
than day 6.
In the serum, the largest rise at day 6 comes from OM to 1.25M NaSCN, whereas in 
CSF, the largest rise is from 2.5M to 5M NaSCN. By day 15, both serum and CSF show 
the largest rise from 2.5M to 5M.
The plot o f total pixel density under the curve shows rises in both serum and CSF over 
time (Table 4.8). As would be expected, as the molarity o f the NaSCN rises, the total 
pixel density drops as lower affinity IgG is removed.
Day Day Day Day
1 6 15 1 6 15 1 6 15 1 6 15
I I I II— I— II— i Peak A 
i i i i i n i i Poly
s c s c s s c s c s c  s c s c s c  s c s c s c
OM 1.25M 2.5M 5M
Figure 4.24 Band/polyclonal and polyclonal areas for ratio calculation in HSE.
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To further underline the point that it is antigen-specific high affinity antibody the pixel 
densities were compared, on the densitogram, of an area corresponding to the peak A 
and underlying polyclonal background (band/polyclonal) and an area of polyclonal IgG 
(see Figure 4.24). Each area was 20 pixels wide and the two were separated by 50 
pixels. Dividing the band/polyclonal area pixel density by the polyclonal area a ratio 
was generated. The figures (see Table 4.11) confirm that at day 1 there was no 
detectable high affinity antigen-specific IgG, there being no detectable signal in the 
areas at any molarity of NaSCN. At both day 6 and day 15 the ratio climbed (except 
between 1.25M and 2.5M for CSF), as the molarity of NaSCN increased, the ratios 
being greatly raised at 5M.
Table 4.11 Band/polyclonal to polyclonal ratio in HSE.
0M 1.25M 2.5M 5M
Day 1 serum 18.10 0 0 0
Day 1 CSF 2.82 0 0 0
Day 6  serum 1.95 7.45 19.85 1008*
Day 6  CSF 2.47 1.81 1.52 6.25
Day 15 serum 1.85 2.62 4.05 338.00
Day 15 CSF 1.35 1.73 1.52 5.58
* Nominal value of 1 given to polyclonal area to avoid division by zero.
4.4 Acinetobacter calcoaceticus in MS
The production of oligoclonal, polyspecific immunoglobulin G (IgG) is characteristic of 
MS, yet no pathogen has been identified as an infectious agent (Talbot et al, 2001; 
Steiner et al, 2001). Recent studies (Hughes et al, 2001; Hughes et al, 2003) have 
proposed Acinetobacter calcoaceticus and Pseudomonas aeruginosa as candidate 
organisms, on the basis of a sequence homology between a bacterial enzyme and bovine
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MBP (Eylar et al, 1970). To investigate this specific, high affinity IgG against these 
pathogens was looked for in paired serum and cerebrospinal fluid (CSF) from MS 
patients compared to other neurological diseases.
The aims of this study were to determine whether MS patients possess antibodies 
against Acinetobacter calcoaceticus, Pseudomonas aeruginosa, Escherichia coli and 
Proteus mirabilis in their CSF and serum, compared to control patients with other 
neurological diseases. Controls included inflammatory diseases of the CNS to assess 
whether any antibodies observed were of high affinity. Proteus mirabilis and
i
Escherichia coli were included as control organisms; Proteus mirabilis as a classic 
enteropathogen and Escherichia coli as it also contains the encephalitogenic sequence 
within its proteins, although not in the same protein. This was carried out using the 
technique of antigen immunoblotting, which involves separating sample IgG by IEF and 
then blotting onto a membrane impregnated with antigen to capture the antibodies of 
interest (Moyle et al, 1984).
Table 4.12 Results for control patients in A. calcoaceticus in MS study.
Patient ID IEF pattern IEF of E. IEF of P. IEF of P. IEF of A.
of total IgG co/i-speciflc mirabilis- aeruginosa- calcoaceticus-
in serum IgG in specific IgG specific IgG speciflc IgG
and CSF serum and in serum in serum in serum and
CSF and CSF and CSF CSF
Cl > Negative Negative Negative Negative
C2 > Mirror (2.5) Negative Negative Negative
C3 * Mirror (2.5) Negative Negative Negative
C4 * Negative Mirror (2.5) Mirror (2.5) Mirror (2.5)
C5 + Negative Negative Negative Mirror (5)
C6 - Negative Negative Negative Negative
C l * Negative Mirror (2.5) Negative Mirror (2.5)
C8 + Mirror (2.5) Negative Mirror (2.5) Negative
Bracketed figure indicates highest molarity of NaSCN at which bands present
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Table 4.13 Results for MS patients in A. calcoaceticus in MS study.
Patient ID IEF pattern IEF of E. IEF of P. IEF of P. IEF of A
of total IgG ^//-specific mirabilis- aeruginosa- calcoaceticus
in serum IgG in specific IgG specific IgG -specific IgG
and CSF serum and in serum in serum in serum and
CSF and CSF and CSF CSF
MSI » Negative Mirror (2.5) Negative Negative
MS2 » Mirror (2.5) Mirror (2.5) Negative Negative
MS3 » Negative Negative Negative Negative
MS4 » Negative Negative Negative Negative
MS5 > Mirror (2.5) Negative Mirror (2.5) Negative
MS6 + Negative Negative Mirror (1.25) Negative
MS7 + Negative Negative Negative Negative
MS8 + Negative Negative Negative Negative
MS9 + Negative Negative Negative Negative
MS10 + Negative Negative Negative Negative
MS11 + Negative Negative Negative Positive (2.5)
MS12 » Negative Negative Negative Negative
Bracketed figure indicates highest molarity of NaSCN at which bands present
Acinetobacter calcoaceticus. Of the eight control samples, three had detectable band 
patterns against A. calcoaceticus, all of them mirror patterns. Two of the mirror patterns 
were visible after incubation with 2.5M NaSCN and the other after incubation with 5M 
NaSCN. Only one of the MS patients had specific bands against Acinetobacter 
calcoaceticus, still visible after incubation with 2.5M NaSCN, which appeared stronger 
in CSF than serum (Figure 4.25).
Pseudomonas aeruginosa. Two patients from both control and MS had mirror patterns 
against Pseudomonas aeruginosa. All of the patterns persisted up to 2.5M NaSCN with 
the exception of one of the MS patients where the pattern could not be seen after 1.25M 
NaSCN.
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Proteus mirabilis. Two control and two MS samples had mirror patterns against 
Proteus mirabilis. All of the patterns were visible at 2.5M NaSCN. Proteus mirabilis 
was chosen as a control organism in its capacity as a classic enteropathogen. 
Escherichia coli. Three control patients had mirror patterns visible up to 2.5M NaSCN, 
but only two of the MS patients, again visible up to 2.5M NaSCN.
Results of antigen blotting are summarised in Table 4.12 for control patients and Table 
4.13 for MS patients.
All samples were also blotted onto a membrane impregnated only with blocking 
solution, (2% skimmed milk and 1% Tris, both weight/volume dilutions) as a negative 
control. One MS patient, MS4, had OCBs that were seen in the serum only. The control 
blot was not exposed to NaSCN as the only bands seen were in the serum of a patient in 
which no antigen-specific OCBs were found.
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Figure 4.25 M irror pattern and positive response to A. calcoaceticus.
Key: A, The typical mirror pattern is represented here by control sample 8, blotted 
against Pseudomonas aeruginosa; B, The strong band (indicated by arrow) in the CSF of 
MS patient 10, blotted against Acinetobacter calcoaceticus. S, serum; C, CSF.
4.4.1 Statistical analysis
Fishers exact test showed no significant difference between MS patients and controls 
for any o f the bacteria studied, Acinetobacter calcoaceticus, p = 0.2553, Pseudomonas 
aeruginosa, p = 1.000, Proteus mirabilis, p = 1.000, Escherichia coli, p = 0.3473.
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4.5 Chlamydophila pneumoniae in multiple sclerosis
The proposal that Chlamydophila pneumoniae could be an aetiological agent in MS 
(Sriram et al, 1999) prompted an investigation into whether the presence of CSF 
oligoclonal IgG correlated with the presence of serum IgG raised against 
Chlamydophila pneumoniae. This was part of a larger study (Furrows et al, 2004) 
designed to look for evidence of current or previous infection in both CSF, using PCR 
and cell culture, and in serum using ELISA and MIF.
In the 27 control patients, none of who demonstrated intrathecal synthesis of IgG, 2 
patients had serum antibodies against Chlamydophila pneumoniae. One had no 
detectable OCBs in CSF or serum and one had a mirror pattern (identical band pattern 
in serum and CSF).
Of the 27 control patients 2 were positive on the Western blot for serum IgG against 
Chlamydophila pneumoniae (7.4%). These were 2 of the 12 patients who were positive 
on ELISA (44.4%); 2 for IgM only, 8 for IgG only and 2, which were positive for IgM 
and IgG. Subsequent analysis by MIF confirmed only 2 of these 12 samples to be 
positive for IgG, two for IgM and one for IgG and IgA. The remaining 7 ELISA 
positives were negative on MIF. Only samples positive by ELISA were subject to 
follow-up analysis by MIF. Thus, 5/27 (18.5%) control patients were antibody-positive 
and 3/27 (11.1%) positive for IgG.
None of the control patients were CSF culture-positive or CSF PCR-positive (Table 
4.14).
In the cohort of 19 MS patients, all of who showed intrathecal synthesis of IgG, only 
one patient, who had no discrete bands of serum IgG, had serum antibodies against 
Chlamydophila pneumoniae. Seven of the MS patients also showed serum OCBs, but 
none of these had a specific response to Chlamydophila pneumoniae in the WB.
Table 4.14 Summary of analyses for controls in G pneumoniae in MS study.
Sample
ID
IEF 
pattern 
of total 
IgG in 
serum 
and CSF
Serum
Western
Blot
ELISA
serology
MIF
serology
CSF
culture
CSF
PCR
2 - Positive IgG Negative Negative Negative
4 - Negative IgG IgG, IgA Negative Negative
5 * Negative Negative Negative Negative
6 - Negative Negative Negative Negative
8 * Negative Negative Negative Negative
1 0 * Negative Negative Negative Negative
1 1 - Negative Negative Negative Negative
14 - Negative Negative Negative Negative
16 - Negative IgG Negative Negative Negative
17 - Negative IgG Negative Negative Negative
18 * Negative Negative Negative Negative
2 1 - Negative IgM Negative Negative Negative
2 2 - Negative IgG, IgM Negative Negative Negative
23 - Negative Negative Negative Negative
24 + Negative IgG, IgM IgM Negative Negative
26 * Negative IgG IgG Negative Negative
27 ♦ Negative Negative Negative Negative
28 - Negative Negative Negative Negative
30 - Negative Negative Negative Negative
36 - Negative IgG IgG Negative Negative
37 - Negative Negative Negative Negative
38 * Positive IgG Negative Negative Negative
62 ♦ Negative IgM IgM Negative Negative
64 - Negative Negative Negative Negative
65 * Negative IgG Negative Negative Negative
6 8 - Negative Negative Negative Negative
69 - Negative Negative Negative Negative
For interpretation of IEF patterns, see Table 1.1. Oligoclonal band pattern reporting in 
Neuroimmunology laboratory, Institute of Neurology.
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Table 4.15 Summary of analyses for MS cohort of C. pneumoniae in MS study.
Sample
ID
IEF 
pattern of 
total IgG 
in serum 
and CSF
Serum
Western
Blot
ELISA
serology
MIF
serology
CSF
culture
CSF
PCR
7 > Negative IgM Negative Negative Negative
9 + Negative IgG IgG Positive Negative
1 2 + Negative Negative Negative Negative
13 * Negative Negative Negative Negative
15 + Negative Negative Negative Negative
19 > Negative IgG, IgM Negative Negative Negative
25 + Negative Negative Negative Negative
29 > Negative IgG IgA Negative Negative
31 + Negative Negative Negative Negative
32 + Negative Negative Negative Negative
34 - Negative IgG Negative Negative Negative
35 > Negative Negative Negative Negative
39 > Negative Negative Negative Negative
52 > Negative IgG Negative Negative Negative
61 + Positive IgG, IgM IgM Negative Negative
63 + Negative IgG IgM Negative Negative
6 6 + Negative Negative Negative Negative
67 + Negative Negative Negative Negative
70 + Negative IgG, IgM Negative Negative Negative
For interpretation of IEF patterns, see Table 1.1 Oligoclonal band pattern reporting in 
Neuroimmunology laboratory, Institute of Neurology.
Of the 19 MS patients only one was positive on the Western blot for serum IgG against 
Chlamydophila pneumoniae (5.3%). This patient had had confirmed Chlamydophila 
pneumoniae infection 6 years previously. This was one of the 9 patients who were 
positive on ELISA (47.4%); one for IgM only, 6 for IgG only and two of which were 
positive for IgM and IgG. Subsequent analysis by MIF confirmed only 1 of these 9 
samples to be positive for IgG, one for IgA and two for IgM. The remaining three 
ELISA positives were negative on MIF. One patient was positive on ELISA for IgM 
only, which was negative by MIF. Only samples positive by ELISA were subject to 
follow-up analysis by MIF. Thus, 4/19 (21.1%) MS patients were antibody-positive of 
which 1/9 (11.1%) was IgG positive.
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Figure 4.26 Two patient sera with serum antibody response to C. pneumoniae.
Key: A and B, respective traces for patients 38 and 2 against C. pneumoniae; C and D, 
respective traces for patients 38 and 2 against control antigen. The control patient, 61, 
was also positive but weakly so and could not be reliably digitised.
One o f the MS patients was positive for CSF culture and a case report was published by 
Furrows et al (2004) but none was CSF PCR-positive (Table 4.15).
4.6 Turbidimetric assay for precipitation by sodium thiocyanate
The purpose o f this assay was to investigate the possibility that 5M NaSCN caused 
precipitation o f protein. It was first observed during the Acinetobacter calcoaceticus in 
MS study that traces on the immunoblots that had been incubated with 5M NaSCN and 
visualised using ECL showed interference that rendered the traces uninterpretable
43 kl)a
16 kPa
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(Figure 4.27). Similar effects were seen with colorimetric development using 
ethylaminocarbazole when studying the difference between a band in the serum and 
CSF of an SSPE patient (Figure 4.28) and subsequently during the attempt to 
demonstrate affinity maturation in an HSE patient.
t  r  > m m
W . b;i. ii’S-i i.
% * j />,« j iic  &  1C
OM 1.25M 2.5M 5M
Figure 4.27 Uninterpretable trace at 5M NaSCN on ECL development.
Uninterpretable trace at 5M NaSCN on chemiluminescent development o f E. coli blot.
OM 1.25M 2.5M 5M
Figure 4.28 Uninterpretable trace at 5M NaSCN on colorimetric development.
Uninterpretable trace at 5M NaSCN on colorimetric development o f SSPE blot.
The results show no trend when NaSCN was added to diluted serum or saline (Tables 
4.16 and 4.17). This would suggest that the addition o f NaSCN did not cause non­
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specific precipitation of protein. The highest response with 5M NaSCN was seen when 
100 pi was added to serum diluted 1/100 (Table 4.16). Likewise, no trends were 
observed with the addition of 10M NaSCN, which was used to compensate for possible 
dilution effects of adding 5M NaSCN to diluted serum (Table 4.17). The highest 
responses were seen when 100 pi of 10M NaSCN was added to the dilutions but the 
largest change occurred when 100 pi of 10M NaSCN was added to saline.
Table 4.16 Effect of 5M NaSCN on goat anti-HSA.
Serum
dilution
A OD340 
5pl
A OD340 
lOpl
A OD340 
25pl
A OD340 
50pl
A OD340 
lOOpl
1/50 -0.003 0.008 0.003 -0.001 0.012
1 / 1 0 0 -0.004 0.013 0.002 0.009 0.030
1 / 2 0 0 0.012 0.001 0.002 0.004 0.019
1/400 0.008 0.013 0.015 .0.024 0.012
1/800 0.010 0.009 -0.007 0.019 0.010
1/1600 0.006 0.016 0.006 0.011 0.012
1/3200 -0.002 0.018 0.014 0.025 0.012
Saline 0.012 0.004 -0.009 -0.002 0.001
Data is shown as the difference in absorbance at 340 nm, (A OD340),
(OD340 sample + NaSCN) -  (OD340 sample + saline)
where the test represents the addition of NaSCN and the control, the addition of saline.
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Table 4.17 Effect of 10M NaSCN on goat anti-HSA.
Serum
dilution
A OD340 
5pl
A OD340 
lOpl
A OD340 
25pl
A OD340 
50pl
A OD340
lOOpl
1/50 -0.005 0.008 -0.012 0.011 0.033
1 / 1 0 0 -0.004 0.018 -0.010 0.014 0.037
1 / 2 0 0 0.003 0.012 -0.017 0.018 0.032
1/400 0.000 0.005 -0.012 0.011 0.030
1/800 0.000 0.011 -0.016 0.013 0.041
1/1600 -0.006 0.017 -0.012 0.012 0.026
1/3200 -0.002 0.003 -0.007 0.023 0.035
Saline 0.005 0.012 -0.030 0.005 0.072
Data is shown as the difference in absorbance at 340 nm, (A OD340),
(OD340 sample + NaSCN) -  (OD340 sample + saline)
where the test represents the addition of NaSCN and the control, the addition of saline.
4.7 Rocket electrophoresis
Rocket electrophoresis was used to estimate serum and CSF IgG of paired samples so 
that the ratios could be determined and hence the appropriate dilutions for IEF. 
Wherever this correction was applied it is referred to in the appropriate sections.
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5.0 Discussion
5.1 Model Method
The aim of this method was to demonstrate that relative affinity could be quantified 
using IEF to separate the clones of IgG, affinity-mediated immunoblotting to capture 
them and NaSCN to probe their relative affinities. Following digitisation of the blot, 
peak areas in pixel density could be calculated and compared and so this is a potential 
method for studying both clonality and affinity of sample IgG to a known antigen, or 
source of antigen. A statistically significant difference was shown between pixel density 
at 5M NaSCN and pixel density at 0, 1.25 and 2.5M NaSCN although there was no 
demonstrable difference between 0, 1.25 and 2.5M. However, trend analysis did show a 
significant trend from OM to 5M. This is best explained by showing that the polyclonal 
background is stripped from the membrane faster than the band of high affinity antigen- 
specific IgG, thus the pixel density of the target band represents a higher proportion of 
the total pixel density under the curve as the molarity of the NaSCN increases. To 
emphasise that it is antigen-specific high-affinity antibody pixel densities were 
compared, from the densitogram, of the target band with an area of polyclonal IgG (see 
Table 4.3, Figure 4.6) for blots 3 and 18. This showed that while there is little difference 
at 0, 1.25 and 2.5M NaSCN, at 5M NaSCN the ratio rises markedly, confirming that the 
polyclonal background is diminished in proportion to the bands of antigen-specific IgG, 
which are of higher affinity.
Ultrabind was chosen as the membrane because of its ability to bind protein covalently. 
The matrix of the membrane is polyethersulphone and it contains aldehyde groups, 
which covalently bind protein molecules through a primary amine group. Covalent 
binding was considered to reduce the possibility of NaSCN stripping antigen from the 
membrane as may happen with other membranes such as nitrocellulose or PVDF, where
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the antigen binds by non-covalent interactions. This makes them vulnerable to a 
chaotrope such as NaSCN, which disrupts non-covalent binding, and so at higher 
concentrations would increase antigen displacement from the membrane alongside 
antigen antibody disruption. Thus, the calculations of relative affinity would be 
artefactually lowered. Comparable blots on nitrocellulose showed areas that had little or 
no colour suggesting that albumin either failed to bind during coating or was removed 
during the assay. Also, background staining with ethylaminocarbazole was higher on 
nitrocellulose than Ultrabind, resulting in the dried nitrocellulose being noticeably 
brown as opposed to the faint pink or white found with Ultrabind. The manufacturers of 
Ultrabind recommend colorimetric detection with chloronaphthol rather than 
ethylaminocarbazole. Although this does result in even lower background, work with 
biological systems suggests that some sensitivity would be lost.
Normal practice in this laboratory is to block membranes using 2% w/v dried skimmed 
milk in 0.9% saline but initial experiments using this block solution showed it to be 
incapable of blocking the membrane fully. It was then attempted to block the membrane 
with 1% Tris in 0.9% saline but this also failed to block the membrane completely. It 
was found that Ultrabind required blocking in 2% w/v dried skimmed milk and 1% w/v 
Tris in 0.9% saline. When focused samples of anti-albumin IgG were blotted onto a 
milk-coated or Tris-coated membrane, faint IEF patterns could be seen at all molarities 
of thiocyanate. When dried skimmed milk and Tris were combined, no patterns could be 
seen suggesting that milk proteins or Tris alone were not capable of saturating the 
aldehyde groups of the membrane that covalently bind proteins. The pore size of 
nitrocellulose and Ultrabind are the same, 0.45 pm, so although milk is probably 
capable of blocking the polyethersulphone matrix of the membrane, as it does in 
nitrocellulose, Tris, with its primary amine group, is probably more efficient at blocking 
the aldehyde groups.
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Antiserum was diluted at 1/1000 to avoid problems with saturation whereby bands on 
the developed membrane are visible on the reverse of the membrane. This is thought to 
be lower affinity antibody that passes through the membrane quickly (Luxton and 
Thompson, 1989). Saturation can also manifest as heavy, non-discrete staining on the 
front (developed) side of the membrane. This was not acceptable for the process of 
quantifying the bands which needed linearity. Double-dilution of the anti-human 
albumin down to 1/16000, gave progressively fainter patterns, both with respect to 
dilution at the same molarity of NaSCN and at the same dilution over different 
molarities of NaSCN. When the antiserum was diluted to 1/2000 throughout a single 
experiment, it was found that the traces lacked consistency.
In accordance with previous work (Pullen et al, 1986; Luxton and Thompson, 1990) and 
previous studies in this laboratory, NaSCN was used as it had been shown to be an 
efficient chaotrope. Initially, 10M NaSCN was used as the highest concentration but it 
was found that it stripped almost the entire antibody from the membrane. As a result 5M 
NaSCN was adopted as the highest concentration, which was in line with previously 
published work, both with ELISA and immunoblots. Given that the commercial 
antiserum was rich in high affinity antibody to human albumin, incubation with NaSCN 
was for 30 minutes. Observations in this laboratory suggest that this should be reduced 
when studying biological systems as the antigen source may not be pure nor may the 
antibody response be as strong.
Initially, gels were run according to the method of Keir et al (1990) but subsequently 
gels were focused at starting conditions of 800 V, 150 mA and 20 W for 900 volt hours. 
This was because a number of traces showed a pronounced “bend” when developed 
which made them unsuitable for quantitative analysis. To counter this problem, possibly 
caused by excess heat from the electrophoresis the voltage was reduced (and hence, the 
heat) and thus extended the run time whilst maintaining the volt hours. A domestic fan
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was directed onto the tank whilst running to increase heat removal from the system. To 
ensure that the current was equally applied across the width of the gel the electrodes 
were cleaned with 1:1 methanol: water after each run to remove any deposits which may 
have built up during the run and interfered with conduction. The electrodes were also 
cleaned monthly with a 1% Decon (Decon Laboratories Ltd.) solution.
The first antibody, RAG, was applied at a 1/2500 dilution in 0.2% skimmed milk in 
saline and second antibody, SAR conjugated to HRP, was applied at 1/5000 dilution,
i.e. 10 pi in 25 ml and 5 pi in 25 ml, respectively. Had the membrane been left intact, 
rather than being divided into four parts, then a total of 40 pi of first antibody would 
have been used but the dilution volume would have been reduced to 50 ml. Therefore, a 
slightly lower absolute amount of first antibody was used than in the IEF method for 
OCBs routinely used in this laboratory, which uses 50 pi. However, the second antibody 
dilution would have been the equivalent of 20 pi across the whole membrane as 
opposed to the 50 pi routinely used for IEF. This reflects the more sensitive nature of an 
assay detecting specific IgG rather than total IgG, which is detected by IEF for OCBs. 
Digitised images were saved as greyscale TIFFs because of the universal nature and 
ease-of-use of these formats. This allowed us to standardise all blot analyses by 
calibrating with a commercially-produced and freely available standard curve, in the 
form of a graded step tablet, and to express results in terms of optical (pixel) density, 
which is an internationally recognised unit of measurement. The only drawback was the 
need for access to a scanner capable of scanning high resolution images; the software 
used (Irfanview and ImageJ) are both available as free downloads from the internet, 
ImageJ being a Java-based program that is platform-independent.
The same batches of commercially available antigen and antiserum were used in all 
blots to remove two potential sources of variation across all experiments and were 
deliberately chosen so that the method could be repeated by other workers to verify the
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results. Commercial antigen and antiserum should have little batch-to-batch variation 
with regard to purity and activity, and therefore represent the optimal form of the 
method; “in-house” or commercial preparations of bacterial and viral antigen will not 
necessarily be as pure. The purity of the human albumin meant that, compared to 
bacterial antigen preparations or even commercial viral antigen preparations, a much 
lower protein load was necessary to sufficiently coat the membrane with antigen. 
Likewise, the commercial anti-human albumin antiserum was rich in specific high- 
affinity antibodies to human albumin due to repeated immunisations of the source 
animal, resulting in strong and consistent patterns when the two were combined. For 
these reasons, it would be recommended that in such experiments preliminary studies 
are conducted to determine an appropriate coating capacity and sample dilutions should 
also be studied to determine an optimum dilution for the level of coating. Preferably, the 
antigen will be in excess, allowing the capture of the maximum amount of antibody, 
whilst maintaining a low polyclonal background.
To confirm that the anti-human albumin antiserum did indeed contain high affinity 
antibodies against human albumin a modified version of the affinity distribution was 
performed (Luxton and Thompson, 1990) using OM (saline), 1.25M, 2.5M, 5M and 
10M NaSCN. This showed that high affinity antibodies were present at both 5M and 
were even detectable at 10M NaSCN thus providing confirmation by another method of 
their presence.
5.2 Comparison of band in serum and cerebrospinal fluid
A paired sample of serum and CSF was taken from a patient referred to the NHNN with 
a clinical diagnosis of SSPE with the intention of demonstrating that the same clone in 
the CSF and serum was significantly stronger in CSF. Although weak bands could be 
seen by eye they were not always detectable on the densitogram or the scanned image. 
As the concentration of NaSCN increased polyclonal background IgG was lost more
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quickly than antigen-specific IgG thus the samples were more dilute for exposure to OM 
NaSCN so as to maximise the signal from the serum trace whilst avoiding saturated 
areas of the membrane. This could not be done wholly successfully and the 
representative band scanned did not include the whole trace. Nevertheless, the pixel 
density of the area scanned from each trace was identical, as ImageJ allows the same 
box to be applied to each trace and gives co-ordinates to ensure correct positioning. 
Routine IEF of the paired samples revealed the patient to have a “greater than ” ( » )  
pattern that had many more, and stronger bands, in the CSF than in the serum. However, 
affinity-mediated immunoblot revealed a mirror pattern with regard to measles-specific 
IgG. The ratio between the serum and CSF bands remained consistent at each molarity 
for at least two of the three replicates, indicating that the measles-specific serum IgG 
was of largely intrathecal origin, as the ratio was maintained.The mirror pattern is 
almost certainly a reflection of the chronic condition of the patient in that intrathecal 
IgG produced against measles slowly leaches into the systemic circulation. That the 
patient sample was taken at least two months after the first reported symptoms is 
consistent with this conclusion. It may be that the assay is sufficiently sensitive to detect 
the leak from CSF into serum, however, there will also be some production of systemic 
antibody by the Peyer’s patches in response to chronic measles infection. Another factor 
that would affect the different patterns is the blotting techniques used in the two assays. 
In routine IEF the background of polyclonal IgG is greater as total IgG is being 
detected; in affinity blotting, detection is biased towards antigen-specific IgG, therefore 
bands that are “swamped” in IEF can become visible in affinity blotting. A 1:400 
dilution of serum, as in IEF, yields a concentration of 23 mg/1 IgG; in affinity blotting 
the serum dilutions gave 4.4 mg/1 at OM NaSCN and 8.8 mg/1 at 1.25 and 2.5M NaSCN. 
That bands became visible in affinity blotting at lower concentrations suggests that the 
technique, as would be expected, is more sensitive than routine IEF at detecting specific
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antibody. This, of course, is dependent on the amount of specific IgG that is actually 
present in the sample. Moreover, with statistically significant differences between serum 
and CSF replicates at each molarity, it suggests that the method can also be capable of 
distinguishing intrathecally-produced antigen-specific IgG. This agrees with the original 
proposal of Moyle and Thompson (1984), that the technique is capable of detecting low 
levels of antigen-specific antibody, such as would be found in early disease. The sample 
had a normal CSF total protein of 0.36 g/1, usual in SSPE, indicating that blood-brain 
barrier function was intact and that there was minimal passive transfer of systemic IgG 
into the CNS, including antigen-specific IgG of systemic origin.
It could be argued that the polyclonal background in CSF is derived from plasma and 
that including it when calculating peak areas of specific IgG as a percentage weakens 
the test, when comparing serum to CSF. To counter this, simply measuring the peak 
height ratio of serum to CSF could be seen as more appropriate. However, by looking at 
antigen-specific antibody and diluting serum and CSF to the same concentration of IgG, 
background IgG was considerably minimised, which therefore reduced the background 
effect of polyclonal IgG.
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5.3 Affinity maturation in Herpes simplex encephalitis
The diagnosis of HSE (Type 1 Herpes virus) was initially made on the basis of the PCR 
for viral DNA on the first CSF sample being positive. Standard clinical practice is to 
prescribe acyclovir when encephalitis is suspected, even though it may not be caused by 
herpes, and so the patient was on acyclovir from admission. There is only a small 
"window of opportunity" in which PCR will produce positive results (Sindic et al, 2003) 
and that, combined with the acyclovir therapy, is probably responsible for the 
subsequent negative results on PCR in the CSF. Another strong indication of the cause 
of the encephalitis being of viral origin, rather than any other, is the white cell count. 
Normal range CSF white cell count is less than 5 per mm3; the first sample contained 
200 lymphocytes, the second 190 white cells, which were predominantly lymphocytes 
and the last sample contained 36 white cells, again predominantly lymphocytes. 
Lymphocytes are usually found in viral infections whereas polymorphonuclear 
neutrophils (PMNs) are usually raised in bacterial meningitis. The reduction in the 
numbers of lymphocytes over the sixteen days that the samples span is probably a 
reflection of the resolution of the infection by a combination of the immune response 
and the acyclovir therapy. Along with the positive PCR, the white cell counts are 
indicative of CNS infection by a viral agent. Outside of routine diagnostic testing, 
rocket electrophoresis for total IgG in both serum and CSF was also performed. This 
showed that the total IgG in CSF one day after admission was 260 mg/1 which rose to 
845 mg/1 after six days and declined slightly to 696 mg/1 after sixteen days. Normal 
CSF IgG is approximately 25 mg/1, thus levels were 10-fold, 34-fold and 28-fold higher, 
respectively, on days 1, 6 and 16 after admission. Serum levels rose from 7585 mg/1 to 
16367 mg/1 over the same time. This rapid increase in CSF IgG strongly suggests that 
the IgG produced is intrathecal, rather than systemic which nevertheless doubled, 
probably due to accumulation of intrathecal IgG in the serum and some systemic IgG
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production from the spleen against virus particles and fragments entering the systemic 
circulation from the CSF. Thus, it was reasonably certain that the diagnosis of HSE was 
correct.
The total area under the curve, as measured from the densitograms, rose from day one 
through to day three, in both serum and CSF, without exception. The total pixel density 
fell as the molarity of the NaSCN rose in both serum and CSF. However, only at 5M 
NaSCN did the total pixel density in CSF drop below any of the serum total pixel 
density levels, suggesting that the CNS production of high-affinity antigen-specific IgG 
was in higher proportion than in the serum. As the assay was specifically designed to 
capture antigen-specific antibody, this shows that in both serum and CSF, antigen- 
specific high-affinity IgG was being produced whilst low-affinity IgG was being 
progressively removed by stronger NaSCN. Although the amount of high-affinity IgG 
rose in CSF the total IgG dropped slightly between days 6 and 15. This was interpreted 
as the maturing of the immune response, producing more high-affinity IgG, but of 
restricted clonality, a hallmark of affinity maturation. In serum, the total IgG and 
antigen-specific IgG both rose between days 6 and 15, albeit less dramatically than in 
CSF. As the seat of the original infection was in the CNS, the systemic response to the 
herpes virus would start later as viral particles and fragments cross the BBB into the 
systemic circulation. Previous work has suggested that B cell clones may also be 
recruited in the periphery to reinforce the initial intrathecal response (Davies, 1988). 
Ideally, a paired sample from the convalescent phase would have been taken, allowing 
investigation into the clonal range and affinity of specific IgG post infection in serum 
and CSF, but in clinical terms this is not necessary as the illness is resolved or 
resolving. It would be predicted that the total and specific IgG would have returned to 
normal levels and the number of clones would be fewer. However, those clones 
remaining would still be of high affinity.
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The experiment was repeated at two normalised concentrations of total IgG; 52 mg/1 
and 104 mg/1. Although it was apparent that much of the trace at 104 mg/1 would be 
saturated it allowed the investigator to see bands that were far more subtle at higher 
dilutions. More bands were seen in the serum and CSF of the first sample at 104 mg/1 
than in the 26 mg/1 sample but at neither dilution did these bands persist beyond 0M 
NaSCN. Both the second and third samples, diluted at 26 mg/1 and 104 mg/1, showed far 
stronger bands at 0M NaSCN which were still clearly visible at 5M NaSCN. This was 
interpreted as showing that the early sample contained less specific IgG than the latter 
two, which was indicated by rocket electrophoresis for total IgG, and that the specific 
antibody was not of sufficient affinity to resist 5M NaSCN. The later two samples, 
which had approximately three times the total IgG, also contained specific IgG of high 
affinity for herpes virus. The presence of specific IgG of high affinity, it was concluded, 
demonstrated that affinity maturation with regard to herpes virus had occurred from the 
time of the first sample to the time of the second sample.
Interestingly, the experiment at 52 mg/1 was the last one performed on these paired 
samples. The trace itself had run shorter than the 26 mg/1 and 104 mg/1 traces, making it 
somewhat harder to see the bands present. Tellingly, this was the only experiment 
where the "interference" effect at 5M NaSCN was seen. This would suggest that the 
highest dilution, 26 mg/1, was most reliable as this equates to normal CSF levels of total 
IgG, which do not saturate the antigen-coated membrane.
The patient had a greatly raised total protein within the CSF indicating blood-brain 
barrier damage, suggesting that the infection was already established at admission. Poor 
barrier function may allow some passive movement of IgG between the systemic 
circulation and the CNS. As the samples were diluted to parity with respect to IgG 
concentration, rather than assuming that serum could be diluted 1/400 to normalise 
background total IgG, this could have enhanced the appearance of bands in the serum.
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5.4 Acineobacter calcoaceticus in MS
The previous study by Hughes et al (2001) looked at the serum immune response to 
Acinetobacter calcoaceticus, Pseudomonas aeruginosa, MBP and neurofilaments in 
MS, cerebrovascular accident and healthy controls to calculate an index by which MS 
and non-MS could be distinguished. Using a semi-quantitative ELISA they showed 
significantly higher levels of IgG against Acinetobacter calcoaceticus and Pseudomonas 
aeruginosa in serum from MS patients.
As MS is a disease characterised by the intrathecal synthesis of OCBs of IgG, it was 
necessary to determine whether or not any IgG detected was of systemic or intrathecal 
origin. For this paired CSF and serum that were taken contemporaneously were 
compared. With just one possible exception, any patient, either MS or control, who 
showed OCBs in this study, had a mirror pattern implying the IgG was of systemic 
origin. Although this would not rule out an autoimmune mechanism, whereby infection 
of the periphery could lead to activation of autoreactive B cells and production of cross­
reactive antibodies which could then enter the CNS, the results of these assays do not 
support a role. Indeed, there was a higher incidence of the mirror patterns in the control 
patients than the MS patients for Acinetobacter calcoaceticus and equal occurrence of 
Pseudomonas aeruginosa, supporting the lack of association.
The possible exception, mentioned above, was the MS patient blotted against 
Acinetobacter calcoaceticus. Although the same bands were present in both serum and 
CSF, they were of a lesser intensity in the serum, which could suggest they were of 
intrathecal origin. However, the method of visualisation, ECL, does not show a linear 
response and, as sera were routinely diluted 1 in 400 on the basis of normal barrier 
function rather than IgG concentrations being standardised, it was impossible to 
determine whether this was a reflection of the respective concentrations of total IgG.
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Attempts to visualise the results using colorimetric detection were unsuccessful due to 
the relative insensitivity compared to ECL.
Another characteristic of MS is the polyspecific low affinities of the oligoclonal IgG 
intrathecally produced (Luxton et al, 1995). In this study blots were therefore incubated 
with varying concentrations of the chaotropic agent, NaSCN, to determine the affinity 
of any IgG detected. As no evidence of intrathecal synthesis was found, with the 
possible exception previously discussed, the question of affinity became academic. 
However, it was found that the patterns persisted in both CSF and serum up to the same 
concentration of NaSCN, usually 2.5M. In some instances, the blots that were incubated 
in 5M NaSCN were uninterpretable owing to interference possibly caused by the 
NaSCN itself (Bouvet et al, 2001a). The similarity of serum and CSF band patterns 
suggests that the IgG in the CSF is a “leak” from the serum, therefore having the same 
affinity, and does not originate intrathecally.
One of the MS patients, MS4, showed serum, but not CSF, oligoclonal IgG against milk 
proteins on the control blot. The lack of corresponding bands in the CSF is probably due 
to their lower concentration as CSF samples were run undiluted.
The band patterns observed in these experiments bore no obvious relation to those seen 
on the original IEF. The patterns seen were often restricted to a small area of the overall 
trace whereas on the original IEF the bands were distributed widely across the pH 
gradient. What may have been detected was a recent “challenge” to the immune system 
following an encounter with the organism or even the immune memory of a previous 
encounter. It should be noted, however, that the encephalitogenic sequence of MBP is 
recognised by T cell receptors and not necessarily B cells (Mazza et al, 2002) thus there 
may be no intrathecal antibody response. Also, the work by O’Connor et al (2003), 
which could only find low affinity IgG against MBP in MS serum and CSF, suggested 
that MBP was not a major target of autoantibodies in MS. However, this does not
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discount the possibility that antibodies with higher affinity are produced and bound to 
myelin within CNS tissue. Within the confines of this study the results seem to indicate 
that exposure to Acinetobacter calcoaceticus or Pseudomonas aeruginosa does not 
occur at a higher frequency in MS patients compared to those with other neurological 
diseases. It is therefore questionable whether infection with either of the bacteria may be 
involved in a pathogenic autoimmune mechanism leading to MS.
The theory of Acinetobacter sp. causing neurological disease by molecular mimicry of 
MBP was first proposed by Ebringer et al (1997) as a possible cause of BSE, following 
accidental contamination of cattle foodstuffs with bowel bacteria. Further work by the 
same group (Tiwana et al, 1999) found raised serum antibodies to MBP and 
Acinetobacter sp. in BSE-affected cattle though the significance of this was questioned 
(Nielsen et al, 2002). On the basis of the sequence homology between Acinetobacter sp. 
and MBP and the presence of MBP-specific T cell clones in MS patients 
(Wucherpfennig and Strominger, 1995) Acinetobacter sp. were proposed as potential 
aetiological agents in MS. However, the absence of common clinical findings, such as 
demyelination and intrathecal synthesis of IgG in MS, would suggest that there are few 
parallels to be drawn between the two pathologies. The final argument would be the 
level of homology. Usually a sequence of at least eight amino acids is required to be 
homologous for there to be a likelihood of the two antigens containing the same target. 
None of the proposed sequences has more than five homologous amino acids and none 
is in a continuous sequence.
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5.5 Chlamydophila pneumoniae in MS
Following Sriram’s original study (1999), a number of further studies were undertaken 
to investigate the proposed link between MS and Chlamydophila pneumoniae. None of 
these studies, however, could confirm Sriram’s findings. In order to investigate the 
association shown by Sriram et al (1999), similar methodology was used, concentrating 
on CSF culture, CSF PCR and serology. Although the culture of Chlamydophila 
pneumoniae from the CSF of an MS patient is unique in the United Kingdom, PCR 
from this, and all other samples, proved to be negative. Internal controls in the PCR 
proved that 90% of the assays were capable of detecting 125 genomes ml/CSF.
However, although all samples were reported as negative this included those with 
negative internal controls when the sensitivity of the assay was unknown. The culture- 
positive sample had a negative internal control, which may explain the negative PCR 
finding. The serology studies on this one patient confirmed previous infection, which 
supported the finding of serum IgG against Chlamydophila pneumoniae found in the 
Western blotting. One of the two control samples that were positive on the Western blot 
was negative for OCBs in serum by IEF, which was detected colorimetrically, whereas 
the Western blotting was detected by chemiluminescence, a more sensitive method. 
Thus, it may be that the Western blotting was simply detecting circulating antibody 
from previous exposure to Chlamydophila pneumoniae. This would be supported by the 
result from the MS patient.
Although all the Western blot positive patients were positive for IgG by ELISA 
serology, only the positive MS patient was also positive by MIF. Furrows et al (2004) 
found four MS patients and six controls to be positive by MIF suggesting that WB is not 
sufficiently sensitive to replace MIF, the current “gold standard” for serodiagnosis of 
Chlamydophila pneumoniae infection despite attempts to use recombinant chlamydial 
proteins rather than cell line homogenates (Pucci et al, 2000).
In summary, while these results showed that Chlamydophila pneumoniae could be 
cultured from the CSF in 1 of 19 patients with MS, serology did not demonstrate a 
difference in exposure between the two groups, and PCR was negative in all cases. It 
was therefore concluded that within this cohort there was no evidence of systemic 
infection with Chlamydophila pneumoniae being either a cause of or having any 
association with the pathogenesis of MS.
However, the recent Nurses’ Health Study (Munger et al, 2003) suggests there may be a 
positive association between Chlamydophila pneumoniae infection and MS, particularly 
progressive MS. There is therefore a need for well-designed clinical and 
epidemiological studies to produce more direct evidence of a role for Chlamydophila 
pneumoniae infection in MS.
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5.6 Interference studies with sodium thiocyanate
In a number of experiments an effect was observed on focused samples after exposure 
to 5M NaSCN. The effect was manifested as excessive homogenous colour 
development during visualisation along the length and width of the sample trace, 
although not beyond it, which obscured or replaced the expected patterns. This 
suggested that the effect must involve the antibodies in the experiments rather than the 
antigens or blocking proteins, as the latter were distributed across the entire membrane, 
as was the colour reagent at the end of the assay. The effect was observed with ECL and 
colorimetric development, with both ethylaminocarbazole and chloronaphthol, which 
ruled out the possibility that the effect was an artefact of any particular developing 
reagent and it occurred with a number of different samples, suggesting that the effect 
was independent of the samples focused. The effect was not seen on any of the blots run 
to generate data for the model method.
It was hypothesised that the effect may have been due to precipitation of protein by 5M 
NaSCN and set up an ELISA to investigate this. Fifty pi of goat anti-human albumin, 
double-diluted from 1/50 down to 1/3200, with a saline control, were put in an ELISA 
plate and immediately mixed with either 5, 10, 25, 50 or 100 pi 5M or 10M NaSCN.
The samples were diluted in saline, reducing the amount of adsorption of antibody to 
the plate, which normally requires alkaline pH. Any protein precipitation would have 
been most marked at the highest concentrations of antibody and highest volumes of 
NaSCN but there was no discernible trend with either parameter. Indeed, the biggest 
effect was observed with saline and 10M NaSCN which implies that any changes in 
turbidity may be due to the viscous nature of concentrated NaSCN. From this it was 
concluded that the interference effect was not due to protein precipitation. Although 
previous studies had recognised the phenomenon none had identified it on IEF followed 
by affinity-mediated immunoblotting. Gray and Shaw (1993) noted the effect on affinity
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purified monoclonal human IgM which McMahon and Kennedy (2000), looking at 
affinity purified murine monoclonal IgM, thought to be an artifact of the affinity 
purification of the antibody solution. However, as the samples used were not affinity 
purified it was concluded that although the effect may be mediated by affinity 
purification it is not an exclusive effect of it. Bouvet et al (2001a) were more 
comprehensive in their investigations, finding that the effect varied with antibody 
exposed to the chaotrope before being introduced to the assay, and that it was not 
artefactual since different chaotropes were effective. They also showed that the effect 
was probably localised to the F(ab) fragment rather than the Fc and was possibly an 
irreversible conversion rendering the IgG poly-reactive.
Although these studies concentrated on IgG becoming poly- and self-reactive the 
principle of structural alteration of the IgG molecule remains. It is possible that the 5M 
NaSCN in these experiments is modifying the polyclonal, or background, IgG that is 
binding to the antigen on the membrane, rendering it more “visible” to at least one of 
the detector antibodies. Band patterns can still be seen in some of the affected traces but 
it would be difficult to apply any sort of reliable interpretation on them. Another 
observation made was that the effect seemed to increase with the age of the sample.
This implies that the in vivo degeneration of the sample antibodies make them more 
vulnerable to the effects of NaSCN, further suggesting that any alteration is of a 
chemical and therefore structural nature. Interestingly, the model method studies using 
commercial goat anti-human albumin did not suffer from the problem of exposure to 
5M NaSCN even though they were exposed for 30 minutes and the same serum was 
used for a number of weeks. Although the effect does not seem to be species-specific 
with regard to IgM, the same conclusion cannot yet be drawn for IgG as it has only been 
reported in human IgG. The last experiment with the series of patient samples from the 
HSE case demonstrated the effect whereas two previous experiments had not. This
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implies that the increasing age of the samples, possibly due to some natural in vitro 
degradation, may be a factor in their susceptibility to high strength thiocyanate. The 
goat anti-human albumin contains 0.2% sodium azide which normally prevents bacterial 
growth by inhibiting oxidative enzymes. It may be that it also acts as a scavenger for 
oxygen and prevents in vitro oxidation and thus, reduces its susceptibility to alteration 
by NaSCN.
Summary
To summarise: the technique of Eastern blotting allows the objective measurement of 
differences in four key areas of a blot. Differences can be shown between:
1. Serum and CSF.
2. Oligoclonal and polyclonal IgG.
3. Bands.
4. Affinity, by using different molarities of thiocyanate.
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6.0 Conclusions
The results from the model method showed that the relative affinity of clones of 
antigen-specific IgG could be measured by IEF, antigen-blotting and thiocyanate 
elution, followed by digitisation of the blot and investigation with image-processing 
software. As part of this study a covalent-binding membrane was successfully used to 
immobilise antigen, thus reducing the risk of losing antigen at high molarities of 
thiocyanate. Statistical analysis showed a significant trend for peak area (in pixel 
density) as a percentage of the total area to increase with molarity of thiocyanate for a 
high-affinity clone. Thus, it was concluded that this was a valid method for the 
investigation of affinity of antigen-specific IgG. To demonstrate this further, the ratio of 
band plus polyclonal to polyclonal areas was compared for both model method blots, 
the SSPE patient and HSE series blots. These showed the ratio of "band" to "polyclonal" 
increased at 5M NaSCN on the model method blots but increased across all molarities 
on the HSE blot, particularly at 5M NaSCN. The SSPE blot only went up to 2.5M 
NaSCN but nevertheless demonstrated a sharp rise in ratio with increasing molarity of 
NaSCN.
The method was slightly adapted, in terms of antigen load and length of exposure to 
thiocyanate, to investigate clinical cases of SSPE and HSE. When serum and CSF IgG 
concentrations were normalised, antigen-specific IgG bands were shown to be present in 
the SSPE serum whereas at the standard dilution of 1/400 for serum and neat for CSF 
they were not. However, the peak area (in pixel density) of a band in CSF in SSPE was 
significantly higher than that in the serum, indicating that it was of intrathecal origin, 
especially as the CSF total protein was within normal range. In the HSE series, the 
serum bands were still present at 1/400 dilution, reflecting the high amounts of 
intrathecal IgG produced and loss of integrity of the blood:brain barrier. Over time, IgG 
passes from CSF to serum (and sometimes vice versa), thus identical bands can be
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found in serum and CSF even when they originate intrathecally. As samples were 
diluted to parity with respect to IgG concentration this enhanced the appearance of 
bands in the serum.
The method is therefore capable of discriminating between subtle differences and it can 
be used to show differences between IgG affinity of the same band in serum and CSF or 
between bands in the same sample, based on resistance to increasing molarity of 
NaSCN.
Two groups of researchers had separately suggested that Acinetobacter sp. and 
Chlamydophila pneumoniae were potentially infectious causes of MS. Sriram (1999) 
reported significantly higher levels of Chlamydophila pneumoniae by culture and PCR 
in CSF. The claim for Chlamydophila pneumoniae was investigated in collaboration 
with another group by a variety of methods; PCR, serology by ELISA and the more 
sensitive MIF, CSF culture and Western blotting. A cohort of MS patients were 
compared with a control group of other neurological disorders but no difference 
between the two groups was found, leading to the conclusion that infection with 
Chlamydophila pneumoniae did not lead to the development of MS.
Acinetobacter sp. were proposed as causative agents of MS due to a sequence similarity 
between one of the bacterial enzymes and MBP. Antibodies raised against the 
Acinetobacter protein were then thought to cross-react with MBP leading to an immune 
response and subsequent demyelination. A cohort of MS patients was compared with a 
cohort of other neurological diseases by antigen-blotting of paired serum and CSF 
samples against Acinetobacter calcoaceticus, with Pseudomonas aeruginosa, Proteus 
mirabilis and Escherichia coli as control organisms. Again, no difference was found 
between MS and control cohorts and it was concluded that Acinetobacter calcoaceticus 
was not implicated in the pathogenesis of MS.
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As part of the experiments a phenomenon was discovered whereby traces exposed to 
5M NaSCN showed interference, which manifested as a “smearing” effect when the 
blot was visualised. Observations made in this study suggested that the effect was not 
artefactual, as previous researchers had thought, but a genuine effect mediated by high 
strength thiocyanate. It did not appear when using commercial goat serum over many 
weeks, which contains sodium azide as a preservative, but patient samples suffered, 
particularly when stored for longer. Thus, it was concluded that in vitro processes in 
cold-stored serum might render the immunoglobulin more susceptible to modification 
by thiocyanate.
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7.0 Future work
An interesting and unexpected finding was the interference effect of 5M NaSCN. This 
phenomenon needs to be further investigated by studying the effects of age, storage and 
addition of sodium azide to commercial and patient sera to see whether the effect of 5M 
NaSCN can be modified. It does not appear to be an effect of affinity purification, as 
one previous study concluded, but would be helpful to understand some of the causes 
and if possible find a means of prevention, or at least a timescale in which this happens. 
It would also be of interest to study the ratio between bands of IgG in paired samples of 
CSF and serum. Given that there is approximately 10000 times more IgG in the serum 
and Tourtellotte’s argument (1970) that there are insufficient lymphocytes in the CNS 
to generate enough IgG to appear in the serum this may allow the deduction of whether 
the B cell clones producing the IgG remain in the CNS, the presence of IgG in the 
serum being merely an “overspill”, or whether some of the B cell clones are returning to 
the systemic circulation and producing IgG independently.
A recent study (Cepok et al, 2005) has suggested that EBV may be important in the 
pathogenesis of MS. Some of their conclusions were based on IEF followed by blotting 
onto antigen-coated membrane which showed an IgG response to EBV proteins in MS 
patients. This part of their study should be repeated incorporating incubation with 
NaSCN to assess the relative affinities of any antigen-specific IgG found.
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Appendices
Appendix i. Peptides referred to in Acinetobacter calcoaceticus in MS study.
Similar sequences in human MBP, neurofilament protein and MOG to A. calcoaceticus 
and P. aeruginosa. Identical amino acids in red. Retrieved from Swissprot release 41, 
6th March, 2003.
Peptide Source Amino acid sequence Amino acid 
position
Location
1 Human GLSLSRFSWGAEG
OR
110-124 MBP
2 A.
calcoaceticus
QNFISRFAWGEVN
SR
38-52 4-CMLD
3 P. aeruginosa QEMITRHAWGDIW
TR
38-52 y-CMLD
4 Human HARHGFLPRHRDT
GILDS
23-40 MBP
5 A.
calcoaceticus
FKAAQPARKLRDT
GIISV
67-84 Coenzyme pqq 
synthesis 
protein b
6 P. aeruginosa FAPMQPGRALRDT
AIGAI
67-84 Coenzyme pqq 
synthesis 
protein b
7 Human PFSRVVHLYRNGK
DQ
43-57 MOG
8 A.
calcoaceticus
DSYVFDELYRAGK
IE
83-97 3-oxoadipate 
CoA 
transferase 
subunit A
9 Human EISFLKKVHEEEIAE 219-233 NFL
10 A.
calcoaceticus
SNMDDKKVKEEKI
LH
3-17 Regulatory
protein
11 Human KQLQELEDKQNAD
IS
331-345 NFL
12 A.
calcoaceticus
RALIALEDKSNFIE
A
203-217 Protocatechuat
e-3,4-
dioxygenase
13 HPV (type 16) TVIQDGDMVHTGF
GA
219-233 Major capsid 
protein LI
Abbreviations: A, alanine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, 
glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; 
P, proline; Q, glutamine; R, arginine; S, serine; V, valine; W, tryptophan; Y, tyrosine.
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Appendix ii. Names and addresses of suppliers
Amersham pic. Including Hoefer
Amersham Place 
Little Chalfont 
Buckinghamshire HP7 9NA 
United Kingdom
Baxter Diagnostics
Wallingford Road
Compton
Newbury
Berkshire RG20 7QW 
United Kingdom
BDH (VWR International Ltd.)
Merck House 
Poole
Dorset BH15 1TD 
United Kingdom
Becton Dickinson including Plastipak
21 Between Towns Road 
Cowley
Oxford 0X4 3LY 
United Kingdom
BioRad Laboratories Ltd.
BioRad House 
Maylands Avenue 
Hemel Hempstead 
Hertfordshire HP2 7TD 
United Kingdom
BMA Products (Cambrex Bioscience)
Biocity Nottingham 
Pennyfoot Street 
Nottingham NG1 IGF 
United Kingdom
DakoCytomation Ltd.
Denmark House 
Angel Drove 
Ely
Cambridgeshire CB7 4ET 
United Kingdom
Decon Laboratories Limited
Conway Street 
Hove
East Sussex BN3 3LY 
United Kingdom
DiaSorin Ltd.
Charles House 
Toutley Rd.
Wokingham,
Berkshire RG41 1QN 
United Kingdom
Elkay Laboratory Products Ltd.
4 Marlborough Mews 
Crockford Lane 
Basingstoke 
Hampshire RG24 8NA 
United Kingdom
Eppendorf UK Limited
Endurance House 
Chivers Way 
Histon
Cambridge CB4 9ZR 
United Kingdom
Hayman Ltd.
Eastways Park 
Witham
Essex CM8 3 YE 
United Kingdom
Globepbarm
PO Box 89C 
Esher
Surry KT10 9NA 
United Kingdom
Hollingsworth & Vose Company
112 Washington Street 
East Walpole 
MA 02032 
USA
Invitrogen Ltd including GibcoBRL
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF 
United Kingdom
MP Biomedicals
Qbiogene 
Wellington House 
East Road
Cambridge CB1 1BH 
United Kingdom
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United Kingdom
NIH
9000 Rockville Pike 
Bethseda 
Maryland 20892 
USA
Novagen
Merck Biosciences Ltd.
Padge Road 
Beeston
Nottingham NG9 2JR 
United Kingdom
Oxoid Limited
Wade Road 
Basingstoke 
Hampshire RG24 8PW 
United Kingdom
Pall Gelman
Havant Street 
Portsmouth 
Hampshire POl 3PD 
United Kingdom
Perbio Science UK Ltd. (Pierce)
Unit 9
North Nelson Industrial Estate 
Cramlington
Northumberland NE231WA 
United Kingdom
Perkin Elmer (including Wallac)
Chalfont Road 
Seer Green 
Beaconsfield
Buckinghamshire HP9 2FX
Quadratech Ltd.
PO Box 167 
Epsom
Surrey KT18 7YL 
United Kingdom
Roche Diagnostics Ltd.
Bell Lane 
Lewes
East Sussex BN7 1LG 
United Kingdom
Serva
AMS Biotechnology (Europe) Ltd.
63 B Milton Park
Abingdon
Oxfordshire 0X14 4RX 
United Kingdom
Sigma-Aldrich Ltd.
Fancy Road 
Poole
Dorset BH12 4QH 
United Kingdom
Stuart Scientific
Barloworld Scientific Ltd.
Beacon Road 
Stone
Staffordshire ST 15 OS A 
United Kingdom
Vienna University of Technology
Karlsplatz 13 
1040 Vienna 
Austria
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Appendix iii. Protocol for use of Irfanview and ImageJ
IRFAN
Open the image to be analysed.
Under the Image menu select Convert to Greyscale
Under the File menu select Save As, give the file a name and choose file type TIF 
(Under Options select TIFF and tick box for compression -  none)
ImageJ
Under the Edit/Options/Miscellaneous menu select Open Images at 100%.
Open the image to be analysed
Go to Analyze/Calibrate and open the file <calibration.txt>.
Select Function Rodbard from dropdown menu and change Unit to Pixel Density.
Press OK and calibration curve will appear in new window. Shrink down using <-> key 
in top right comer.
On the toolbar the Square icon is already highlighted. Move cursor to top left of where 
required rectangle is to begin. Holding the left mouse button down draw rectangle 
where required on the image.
Go to Analyze/Gels/Select first lane to keep the rectangle.
Move cursor to interior of rectangle, hold down left mouse button and move rectangle to 
next trace. Note: outline of rectangle will move and does not remain on previous trace. 
Go to Analyze/Gels/Select next lane. Repeat until all required traces have been 
captured.
Go to Analyze/Gels/Plot lanes and densitograms will appear in new window.
Straight line tool is now highlighted in toolbar.
Move cursor onto densitogram and delineate peak by holding down left mouse button to 
draw lines.
Continue through all densitograms until all required peaks have been identified.
Select Magic Wand from toolbar. Click once with mouse in each area to be measured. 
Results appear in new window.
Click <x> in top right comer of plots to get options on saving the plots. Note: they will 
be saved with any lines drawn on them. To save results go under File/Save as option 
within Results box not on main ImageJ toolbar. Note: results files are simply a list of 
numbers. It is advisable to make notes on which results go with which peaks as they are 
calculated.
Both Plots and Results files can be opened from main ImageJ toolbar when required.
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